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Abstract
Since the early twentieth century, mice have emerged as the standard
mammalian model organism for biomedical research. When pain relief is
provided during experimentation, it typically comes in the form of transient
and sometimes ineffective analgesics or anesthesia. This thesis proposes an
alternative to the current method of research in the form of an engineered
mouse model in which pain sensing can be ablated before an experiment. An
ERT2-inducible Cre recombinase under the Wntl promoter was designed to
be combined with a floxed Nav1.7 ion channel mouse model. When a 4-
hydrotamoxifan class small molecule is fed to the mouse, Cre recombinase
expression in the peripheral nervous system will disrupt function of the ion
channel involved in inflammatory and mechanosensory pain. Additional
designs for floxed Nav1.6 ion channel and Nax ion-like channel were made to
explore disruption of peripheral cancer-induced neuropathic pain. In parallel
with mouse model development, a survey was conducted to understand the
potential for adoption of this new animal model by researchers. The survey
was sent to IACUC members questioning if this model was needed, as well as
how it may be regulated under the existing protocol approval framework.
Results indicated that there is a both a need and desire for further
refinement strategies within animal research, and that this inducible pain-
free mouse model could be categorized as alternative analgesic upon
sufficient characterization and peer-reviewed publications. Additional input
was provided that will shape testing done on the generated animals to assure
that this model can mitigate animal suffering while still recapitulating
important biological processes investigated in biomedical research.
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Thesis Overview
This thesis (fig. 1) is meant to contextualize the past and present state of
animal suffering in US research institutions, and propose a refinement to the
system in the form of an inducible pain-free mouse model.
First, I explore the evolution of human
opinion on animals and their ability to sense
and perceive stimuli in their environment.
I will then consider the state of animal
welfare within the US and whether treatment
of animals has developed at the same pace as
animal industrialization.
Thereafter, I will review the molecular basis for pain
sensing within vertebrates, with a focus on the
particular ion channels of interest for modification.
Following this, I will describe the design for the
proposed inducible pain-free mouse model. This
will include the initial designs for the system, as
well as the final constructs made and the status of
animal models for testing.
Then, I will describe the survey that was designed
and sent to IACUC members that questions
whether there is a need for further refinement
within the animal, and if so, how the inducible
pain-free mouse model could be used as a
refinement method after sufficient characterization.
Finally, I will discuss the next steps intended for
the project.
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Fivure 1: Thesis flow chari
"Correspondent to discovery and improvement in the
natural world, is reformation in the moral"
-Preface, A fragment on government, Jeremy Bentham
I. A Brief History of Animals in Philosophy
Humans have used animals for their benefit since domestication allowed for
the rapid development of civilization, but it took many years for humans to
recognize these animals as have any capacity for pain and pleasure. The
analysis of the ethics around our treatment of these non-human animals has
developed over time. This section will highlight key philosophers whose
opinions on animal sentience challenged the societal norms that existed in
their time. This will help situate this thesis and the imperative behind the
inducible pain-free mouse project within a moral and ethical context.
I.I Michel de Montaigne
Michel de Montaigne (1533-1592), a French Lord and Renaissance philosopher and
statesman known for his humility, curiosity, and humorous approach to life is held as a
true progressive of his time. He influenced thinkers ranging from Rene Descartes and
Blaise Pascal to Jean Jacques Rousseau and Ralph Waldo Emerson. Montaigne lived
during the Renaissance, a time when classical Greek and Roman thinking was being
rediscovered. Consequently, many of his contemporaries took pride in touting the
superiority of human intellect over all of nature. Montaigne was not so convinced. His
publications were titled "Essais," which translates to "Attempts", popularizing the style
of Essay writing through his seminal works. In his essay Of Cruelty, Montaigne
poignantly notes,
"But when, amongst the more moderate opinions, I meet with
arguments that endeavour to demonstrate the near resemblance
betwixt us and animals, how large a share they have in our greatest
privileges, and with how much probability they compare us together,
truly I abate a great deal of our presumption, and willingly resign that
imaginary sovereignty that is attributed to us over other creatures.
But supposing all this were not true, there is nevertheless a certain
respect, a general duty of humanity, not only to beasts that have life
and sense, but even to trees, and plants. We owe Justice to men, and
graciousness and benignity to other creatures that are capable of it;
there is a certain commerce and mutual obligation betwixt them and
us.
- Of Cruelty, Essays of Michel de Montaign
In a similar vein, he writes in his essay Apology for Raymond Sebond:
'Tis by the same vanity of imagination that he equals himself to God,
attributes to himself divine qualities, withdraws and separates himself
from the the crowd of other creatures, cuts out the shares of the
animals, his fellows and companions, and distributes to them portions
of faculties and force, as himself thinks fit How does he know, by the
strength of his understanding, the secret and internal motions of
animals?-from what comparison betwixt them and us does he
conclude the stupidity he attributes to them?... The defect that hinders
communication betwixt them and us, why may it not be in our part as
well as theirs? 'Tis yet to determine where the fault lies that we
understand not one another,-for we understand them no more than
they do us; and by the same reason they may think us to be beasts as
we think them."
-Apology for Raymond Sebond, Essays ofMichel de Montaigne
Montaigne makes in clear in his statements that he is going against the
commonly held "presumption" that humans have dominion over all other
creatures. At the beginning of the statement on animals made in Apology to
Raymond Sabond, Montaigne claims that presumption of man is "our natural
and original disease." It is no coincidence that the word comes up twice in the
context of humans' treatment of animals. This presumption is what has
allowed humans to attribute "stupidity" to these animals, without any
concrete proof support the claim. Furthermore, Montaigne points to the
vanity of man as the reason for not giving animals "portions of faculty and
force." He does not go as far as to claim that animals and humans are equal
in their metal faculties, but acknowledges that they have something similar
that, though hard to understand, does exist.
These statements are progressive for a writer in the 19th century, let alone
the 16th. More than that, Montaigne maintains that there a societal duty for
humanity to make sure that things that have "life and sense" as well as other
living things, to be respected. Humanity owes "benignity" to creatures,
though he does not elaborate on what that would look like. It would not be
out of line to say that Montaigne would believe that respecting the lives of
these creatures and not causing them undue suffering is within the realms of
"benignity."
I.II Descartes
Ren6 Descartes (1596-1650) is largely considered the father of Western
philosophy. Descartes was a French natural scientist and mathematician, but
above all a rationalist. For his life-long foray into philosophy, Descartes
focused on that which could be confirmed through the senses. Influenced by
Montaigne's notion that humans should study themselves before they buy
into into the thoughts of previous thinkers, he was uninterested in believing
in something simply because someone intelligent in the past had said it.
Instead, Descartes desired to re-derive every philosophical tenet he believed
in.
He coined the phrase "Je pense, doncje suis, "which is translated to "I think,
therefore I am" (Descartes 1969). Descartes believed in a soul-body
separation which made man unique among other living things.
This belief can be seen in his opinion on humans and animals in Part V of
Discourse on the Method, entitled "Physics, the heart, and the soul of man
and animals." In it, he states:
"Such persons will look upon this body as a machine made by
the hands of God, which is incomparably better arranged, and
adequate to movements more admirable than is any machine of
human invention... but if there were machines bearing the image
of our bodies, and capable of imitating our actions as far as it is
morally possible, there would still remain two most certain tests
whereby to know that they were not therefore really men."
- Part V, Discourse on the Method
Descartes is stating that both human and animal anatomy can be thought of
as highly complex machines. He brings up the key difference between the
two in his two tests that distinguish humans above animals. The two tests
are:
1. Animals do not have the ability to arrange any combination of "words
or other signs" in order to declare their thoughts
2. Though there are animals that have the physical capability to perform
many actions well, it would eventually become obvious that these
actions the animal is performing are not from their own knowledge or
reason but just a "disposition of their organs"
Where does that leave our understanding on Descartes' conception of the
faculties of animals? Can an animal have any type of "feeling," and if so,
could it process and understand that feeling without a soul? This is the
premise of a long-standing argument regarding Descartes' beliefs on the
automata-like nature animals implying that animals are incapable of feelings
of any kind, termed the "monstrous thesis."
An oft-quoted piece of a letter to Henry More sent in February 1649 is
brought as further proof that Descartes believed in the "monstrous thesis":
".. it seems reasonable since art copies nature, and men can make
various automata which move without thought, that nature should
produce its own automata much more splendid than the artificial ones.
These natural automata are the animals."
-Letter to Henry More February 5, 1649
Many philosophers use this assignment of animals as "b6te machine," or
animal machines, to jump to the conclusion that Descartes believes in the
monstrous thesis, though Descartes beliefs are more unclear than the strict
divide he has implied.
Reading through Discourse it is clear that Descartes thinks animals can
respond to stimuli, even if they do not possess the ability to reason and
rationalize. He notes:
'And, in the last place, what above all is here worthy of observation, is
the genera tion of the animal spirits, which are like a very subtle wind,
or rather a very pure and vivid flame which, continually ascending in
great abundance from the heart to the brain, thence penetrates
through the nerves into the muscles, and gives motion to all the
members.. .and we ought not to confound speech with the natural
movements which indicate the passions, and can be imitated by
machines as well as manifested by animals."
So the question becomes not whether an animal can respond to a painful
stimulus and respond, but whether it matters that they are responding if it is
an automatic response that does not have thought or reason behind it. In his
analysis of Descartes, John Cottingham points out that in the letter to John
More, Descartes clarifies the difference between the concepts of sensation
(sensus) and thought (cogitatio). (Cottingham 1978) (Descartes 1970).
Descartes states:
"...though I regard it as established that we cannot prove there is any
thought in animals, I do not think it is thereby proved that there is
not, since the human mind does not reach into their hearts."
-Letter to Henry More February 5, 1649
The above statement certainly takes a more Montaigne-esqe approach than
we have seen so far, which is not surprising given Descartes was influenced
by his writing. Both Descartes and Montaigne seem to err on the side of
caution when considering animals, though Montaigne seemed to believe
"conscious unless proven otherwise" whereas Descartes believed "unconscious
unless proven otherwise," as given by his two tests.
When considering what Descartes' final stance is on the matter of the feelings
of animals, it is still unclear. Peter Harrison's analysis emphasizes the habit
of Descartes to employ skepticism whenever unsure of something (Harrison
1992). But does this uncertainty about the animal soul mean that Descartes
did not think animals could feel pain? He certainly agrees that animals have
the capability of sensing and responding to pain. And if he does not think
animals have a soul and can feel physical stimuli in any meaningful way,
does that mean he may encourage animal cruelty? There is no indication of
the sort.
I.III David Hume
David Hume (1711-1776) is seen as one of the most important thinkers of his
time for eschewing Descartes' will to put mind over all, instead prioritizing
human feeling. He believed that most humans act not on rationality, but on
their passions. Hume focused on understanding the similarities between non-
human and human animals in contrast to the Cartesian method of the
differences between the two. It should be noted that while Descartes believed
in God, and therefore a divine soul, it is debated whether Hume was even a
Theist, so the soul was not necessarily a meaningful divider to him between
man and beast.
In his essay "Of the Reason of Animals," Hume confidently states:
'Next to the ridicule of denying an evident truth, is that of taking much pains
to defend it; and no truth appears to me more evident, than that beasts are
endow'd with thought and reason as well as men. The arguments are in this
case so obvious, that they never escape the most stupid and ignorant...
Nature may certainly produce whatever can arise from habit: Nay, habit is
nothing but one of the principles of nature, and derives all its force from that
origin"
-Part III Section XVI, A Treatise of Human Nature
Hume points out that the commonality between behaviors in human and non-
human animals cannot be denied. In his opinion, the most likely scenario is
that both are derived from a common source. This opinion comes a century
before the ideas of natural evolution started taking hold in society. It speaks
to Hume's foresight that this statement sounds obvious, even while being
quite a radical thought at the time.
I.LV Jeremy Bentham
Jeremy Bentham (1748-1832) is considered to be the father of Utilitarianism.
Bentham was hugely impacted by Hume and his focus on the passions as the
most important aspect of the human experience, which drove a lot of his
work. As one who completed his studies at Oxford and was called to the bar
by the age of 21, Bentham had intimate knowledge of a legal system he
quickly came to despise. While writing about reforms for the British legal
system he realized he wanted much more than just reform in one area of
society (Crimmins 2018). Bentham set out to write a complete code of laws, a
"pannomiom" as he referred to it, according to his own moral philosophy.
Bentham's fundamental axiom was "it is the greatest happiness of the
greatest number that is the measure of right and wrong' (Bentham 2001).
Bentham focus strongly on the axis of pleasure and pain, creating a "felicific
calculus" for those who were interested in quantifying any given experience.
In Chapter Four of Introduction to the Principles of Morals and Legislation,
seven different variables are given which can define any experience on the
pain/pleasure axis (Bentham 1996). Those are:
(1) its intensity
(2) its duration
(3) its certainty or uncertainty
(4) its nearness or remoteness.
(5) its fecundity
(6) its purity
(7) its extent
Bentham felt these principles to be so important that he even came up with a
mnemonic doggerel, a catchier way to remember his felicific calculus:
"Intense, long, certain, speedy, fruitful, pure-
Such marks in pleasures and in pains endure.
Such pleasures seek if private be thy end:
If it be public, wide let them extend
Such pains avoid, whichever be thy view:
If pains must come, let them extend to few."
Bentham did not reserve the right to a felicific life to humans alone. He was
more outspoken than his predecessors on the rights of animals, and any
sentient being for that matter, to the right of avoiding pain and increasing
pleasure throughout their lifetime.
"It may one day come to be recognised that the number of the legs, the
villosity of the skin, or the termination of the os sacrum, are reasons
equally insufficient for abandoning a sensitive being to the same fate.
What else is it that should trace the insuperable line? Is it the faculty
of reason, or perhaps the faculty of discourse? But a full-grown horse or
dog is beyond comparison a more rational, as well as a more
conversable animal, than an infant of a day, or a week, or even a
month, old. But suppose they were otherwise, what would it avail? The
question is not, Can they reason? nor Can they talk? but, Can they
suffer?"
-Chapter XVII, Section I, The Principles of Morals and Legislation
Bentham's philosophy of "the greatest good for the greatest number" means
that the systematic nature of millions of animals today suffering under the
control of humans is extremely problematic. The suffering of those animals is
significant, just as significant as human suffering. To him, it is social
obligation to mitigate this suffering and increase the quality of life of these
sentient creatures.
I.V Charles Darwin
Charles Darwin (1809-1882), considered the father of evolution, had much to
say about animal welfare. As someone who saw humans and monkeys as
close cousins, it is not hard to believe that Darwin would have much
sympathy for the pain and suffering of animals. Lingering feelings within the
scientific elite that held humans as far superior to animals was shattered
with the development of the theory of evolution. In addition to publishing On
the Origin of Species, he had written The Expression of the Emotions in Man
and Animals. This book is a fascinating look at how humans analyzed both
themselves as well as non-human animals during this period. Going against
the theories of Sir Charles Bell and Descartes who believed that true emotion
can only be expressed through a divinely-imbued aspect to the person,
Darwin took a more evolutionary approach. He studied both human and non-
human animal expressions, and tried to understand how one may have been
derived from the other. In the introduction the the book Darwin notes:
"Consequently, when I read Sir C. Bell's great work, his view, that
man had been created with certain muscles specially adapted for the
expression of his feelings, struck me as unsatisfactory. It seemed
probable that the habit of expressing our feelings by certain
movements, though now rendered innate, had been in some manner
gradually acquired. But to discover how such habits had been acquired
was perplexing in no small degree. The whole subject had to be viewed
under a new aspect, and each expression demanded a rational
explanation."
-Introduction, The Expression of the Emotions in Man and Animals
Darwin employs a methodical approach to the development of emotions,
using the same law of parsimony he employs when understanding all aspects
of the development of animals. In reference to the emotion of pain, Darwin
states:
Great pain urges all animals, and has urged them during endless
generations, to make the most violent and diversified efforts to escape
from the cause of suffering.. .As the muscles of the chest and vocal
organs are habitually used, these will be particularly liable to be acted
on, and loud, harsh screams or cries will be uttered. But the advantage
derived from outcries has here probably come into play in an important
manner; for the young of most animals, when in distress or danger, call
loudly to their parents for aid, as do the members of the same
community for mutual aid.
-Chapter III, The Expression of the Emotions in Man and Animals
Darwin emphasizes the similarity both in physical and emotional responses
between human and non-human animals when physical pain is inflicted upon
them. He uses words like "distress" to describe an animal's response to pain,
and if employing Bentham's concept of a felicific calculus, it is clear that
animals are in a state they would rather not be in if given the choice. Why
then, is so much of human pleasure built upon a framework on systematic
animal suffering?
I.VI Peter Singer
Peter Singer (1946- ) is one of the most well-known contemporary utilitarian
thinkers as well as a leader in the Animal Liberation movement. Grounded in
Bentham's utilitarianism, Singer believes in addressing as well as making
strides to decrease the suffering of all sentient beings. Bentham's famous
question question "Can they reason? nor, Can they talk? but, Can
they suffer?" drives much of Singer's animal welfare work. It informs his
views on who has power and how that power is used to increase good for the
most. His book Animal Liberation, first published in 1975, is one of the
seminal boots associated with the animal rights movement.
Singer points out that humans practice speciesism, a term coined by animal
activist Richard Ryder (Ryder 1998). Speciesism is a bias where members of a
species have a preference towards one another over other species. This can be
seen in the human attitude towards animals, putting their pleasure over the
suffering of animals and taking moral issue with killing even the most
mentally impaired human over the most sentient non-human animal.
Singer does not emphasizes equality in all aspect between humans and
animals, but equality in consideration (Singer et a]. 1998). In reference to the
current animal experimentation practices, Singer states:
" The experimenter, then, shows a bias in favor of his own species
whenever he carries out an experiment on a nonhuman for a purpose
that he could not think justified him in using a human being at an
equal or lower level of sentience, awareness, ability to be self-directing
etc. No one familiar with the kind ofresults yielded by most
experiments on animals can have the slightest doubt that if this bias
were eliminated the number of experiments performed would be a
minute fraction of the n umber performed today."
Singer feels that if humans would not use an infant or a person who has
severe mental disabilities that prevent him or her from understanding and
making active choices in his or her own life, that humans should not put
preference to these individuals over non-human animals that have the same
or possibly higher cognitive abilities.
This opinion is in contrast to the opinions held by Descartes, who himself has
stated in the Discourse Part V,
"it is incredible that the most perfect ape or parrot of its species,
should not in this be equal to the most stupid infant of its kind or at
least to one that was crackbrained, unless the soul of brutes were of a
nature wholly different from ours."
Singer's statements are meant to make humans uncomfortable. His intention
is to force us into questioning our place within this world and be confronted
by the face that humans clearly place their pleasure at the expense of the
suffering of millions of sentient beings.
LVII David Foster Wallace
David Foster Wallace (1962-2008), is a writer known for his frank analysis
and excessive use of footnotes. His essay on the Main Lobster Festival,
Consider the Lobster, Wallace brings up may points that have roots in the
philosophers just quoted (Wallace 2005).
Within his analysis, DFW first notes the differences in the nervous system of
lobsters compared to humans and organisms that have cerebral cortices with
which to process feelings of emotion. This lobster nervous system of course
does not apply to the vertebrates that are currently used as models in
biomedical research, but it harkens back to some of the Cartesian ideas
around the ability for animals to process the stimuli they experience (though
in his argument it was due to a lack of a soul instead of higher order brain
function).
DFW goes on to explain the complexity of trying to understand pain, which in
itself is a challenge because it is a subjective mental experiences. He notes:
"The fact that even the most highly evolved nonhuman mammals can't
use language to communicate with us about their subjective mental
experience is only the first layer of additional complication in trying to
extend our reasoning about pain and morality to animals."
This statement has traces of Montaigne, recognizing that the fundamental
difficulty in humans properly understanding animals should not preclude
animals from having their own complex way of thinking, feeling, or
experiencing. Humans should not be so vain or presumptuous as to jump
from not understanding animals to imply that they do not equal us in other
ways outside of verbal communication. In this regard though, Descartes
would disagree with Montaigne and DFW. He would stand by the idea that
though animals might have bodily passions and respond to stimuli, it is in
fact akin to a cog moving that would produce a mechanical response in an
automaton. Animals do not have a soul, which is required for processing and
reasoning aspects within humans. So though he may agree that an animal
should not be put in a painful situation, he would certainly not do it on the
basis of an animal's "mental experience."
DWF gets more into the details of how ethicists decide whether there is a
moral imperative to respond to imposed suffering on organisms, with the
criteria being:
"One is how much of the neurological hardware required for pain -
experience the animal comes equipped with-nociceptors,
prostaglandins, neuronal opioid receptors, etc. The other criterion is
whether the animal demonstrates behavior associated with pain."
These two conditions have roots in both the Animal Liberation movement as
well as overarching utilitarian belief systems. Singer, Bentham, and Hume
would all agree with these criteria as important points to consider when
determining pain and pleasurable states for an organism to exist within.
Introducing the concept of pain and pleasure as perceived by the animal
indicates that there is a preferred state of that organism. This becomes a
moral obligation for society to try and make sure we are maximizing the
pleasure experienced by the most for all organisms that demonstrate a
preference away from suffering, like what the above two criteria do define.
Wallace ends with a statement that is as applicable to the field of biomedical
research as it is to the morals of human animal consumption:
"Is it not possible that future generations will regard our own present
agribusiness and eating practices in much the same way we now view
Nero's entertainments or Aztec sacrifices? My own immediate reaction
is that such a comparison is hysterical, extrem e-and yet the reason it
seems extreme to me appears to be that I believe animals are less
morally important than human beings; and when it comes to defending
such a belief even to myself I have to acknowledge that (a) I have an
obvious selfish interest in this belief since I like to eat certain kinds of
animals and want to be able to keep doing it, and (b) I have not
succeeded in working out any sort of personal ethical system in which
the belief is truly defensible instead ofjust selfishly convenient.
This point drives home that philosophy can only go so far in incentivizing
humans to make personally uncomfortable changes in their life. Using
animals is convenient. Mice are well characterized and bred in numbers that
make them an extremely appealing option within biomedical research and a
standard set within the scientific community. Similar to Wallace, who
confesses "my own main way of dealing with this conflict has been to avoid
thinking about the whole unpleasant thing," many a researcher dissociates
the animals they work with during their interactions because of the
emotional toll. Even at a point when it is absolutely morally indefensible,
humans usually need more than philosophy, and at times even lived
experience, to bring about systemic change.
"All the arguments to prove man's superiority cannot
shatter this hard fact: in suffering the animals are our
equals"
-Peter Singer
II. Research Animal Welfare in the United States
The history of animal welfare in the United States has been a multi-century
push to protect animal exploitation and unnecessary suffering. Though there
is a long history of protection against animal cruelty for domesticated
animals, particularly ones raised for slaughter and consumption, this section
will focus on the history of animal welfare as it pertains to those non-human
animals used for research purposes. It will then question whether the current
state of the field where it should be, and if not, what can be done.
II.I Anti-Vivisection Movement
One of the first movements supporting the welfare of research animals used
in the United States was created in solidarity with the Anti-vivisection
movement in England. Vivisection is the practice of performing operations on
living animals, commonly done in animal research. The organization first
fought to regulate the use of animals in science but then pivoted to pushing
for the complete abolition of live animal experimentation in the US. The
Gallinger Bill was brought before Congress in 1900, mirroring the British
Cruelty to Animal Bill of 1876, which requested regulation on scientific
experimentation (Gallinger, 1900). Unfortunately, the bill did not pass and
the movement did not stir the same response in the US as it did in England
to further protect animals from experimentation.
II.1I The Principles of Humane Experimental Technique
In 1954, biomedical research in the US was moving at a rapid pace. At the
same time within the United Kingdom, the Universities Federation for
Animal Welfare (UFAW) had commissioned a research study on how to
advance more humane techniques within the field of animal experimentation
(National Research Council (US) Committee to Update Science 2004). The
two men assigned to the study were William Russel, a zoologist, and Rex
Burch, a microbiologist. Together, they toured labs all over the UK and
analyzed how animals were used in research experiments. They report they
generated for the UFAW was turned into The Principles of Humane
Experimental Technique (1959).
Within this book, the two discuss the current state of pain and distress
experienced by animals, as well as "how humanity can be promoted without
prejudice to scientific and medical aims" (Russel, Burch, and Hume 1959).
They proposed the "3 R's" within animal welfare: replacement, reduction,
refinement. Replacement aims to find alternatives to using vertebrates for
research whether it be cell culture or a microorganism. Reduction aims to
limit the number of vertebrates that will be used through strategic planning
of experiments, proper controls, and careful design. Finally, refinement aims
to assure that the procedures and animal choice are the best fit for the
experiment and will be the least inhumane method of performing the
research. This includes techniques that are the noninvasive, that provide
appropriate anesthetics and analgesics, and providing species-appropriate
enrichment for the animals.
Though this survey was done in the United Kingdom, it has become an
internationally set approach for the human treatment of animals and has
made strides by providing a framework that can adapt over time with new
techniques (Fenwick, Griffin, and Gauthier 2009).
II.1I Laboratory Animal Welfare Act of 1966
In early 1966, a piece in LIFE magazine caused the necessary uproar needed
to make changes to a grossly unregulated field (Cosgrove 2014). The article,
titled Concentration Camps for Dogs and focused on a dog named Pepper who
had disappeared in Pennsylvania only to turn up euthanized in New York.
What followed was an expose on the cruel and horrifying black market that
existed for dogs (stolen or bred) used for vivisections experiments in medical
research. This article prompted an outcry from the public, with letters
flooding Washington that demanded change.
In response, the Office of Animal Laboratory Welfare (OLAW) was
established in 1966 upon the signing of the Laboratory Welfare Act. The
United States Department of Agriculture (USDA) and Animal and Plant
Health Inspection Service (APHIS) were put as the agencies that oversaw
this bill. This piece of legislation is the only Federal law in the United States
that regulates animals for uses such as research, transport, an exhibition
("Animal Welfare Act", n.d.). It covers any cat, dog, hamster, rabbit,
nonhuman primate, guinea pig, and any other warm blooded
animal determined by the Secretary of Agriculture, living or dead. Notable
exclusions from this law include rats, mice, birds, cold-blooded animals, and
farm animals.
Many concepts adopted within this regulation come from the framework that
Russel and Burch has designed. The regulations emphasize the replacement,
reduction, and refinement of animal experimentation whenever possible.
While this law was an important first step towards improving the welfare of
animals, it has only set the minimum level of acceptability within the US and
leaves much to be desired.
Notably though, a 1986 amendment to this law established the institutional
animal care and use committee (IACUC) to be required in all federally funded
institutions performing animal research. This amendment allows for a
critical analysis of all research experimentation on animals taking place in
an institution and creates a formal structure for research protocol approval
as well as reporting. It is certainly a necessary step towards proper oversight
within experimentation.
II.III Animal Liberation Movement
The Animal Liberation Movement was started at Oxford University in the
early 1970's by a group of philosophy students. The movements have roots in
much of the original Anti-Vivisection protesting that was done in the 1800's
around animal experimentation. These students spent their time discussing
points with each other and pulling from past thinkers to assure that their
arguments were both powerful and rational. A core ideal in the movement is
moving away from the "speciesism" that takes place in current human-non/
human animal interactions. The group has done work uncovering violations
in animal rights laws by corporations, boycotted companies and produces that
do not properly care for animals, and performed both symbolic and direct
actions to further their mission.
Amendments made to the Animal Welfare Act reflecting the need for a more
robust protection for animals is due in part to the work of the Animal
Liberation movement. These amendments expanded the animals included
under the policy as well as required the use of analgesics and anesthetic to be
used during experimentation.
II.IV PHS Policy
Though the Animal Welfare Act aimed to improve the conditions of animals
within the US, research fields were still in need of further regulation. The
vast majority of animal research is performed in mouse models, with
estimates being as high as 100 million mice used per year ("Mice and Rats in
Laboratories" I PETA ). Under the initial AWA regulations there was no way
to regulate both the the number and conditions of these animals.
In 1985, the Health Research Extension Act implemented referred to as
"Animals in Research" was passed. This piece of legislations is a requirement
for the National Institute of Health (NIH), not US citizens individually. As a
government funding agency, the NIH invests tens of billions of dollars in
research money every year to public and private research institutions ("PHS
Policy on Humane Care and Use of Laboratory Animals," n.d.). This law
requires that there be compliance in reporting on all vertebrate species for
those awarded funding through the NIH through IACUC committees. This
means that all mouse and rat experiments must be reported.
II.V Changing the System
Though animal welfare has made strides through the establishment of
regulations attempting to prevent undue suffering within the animal
community, it does not mean that these laws are necessarily effective. It has
been shown that fewer researchers, not more, have been seen to implement
the legal standards set for the animal experimentation field (Balcombe,
Ferdowsian, and Briese 2013). Furthermore, though there are requirements
for the delivery of analgesics, most are delivered at the time of surgery and
there is little to no post-operative care or treatment of persistent research-
related pain (Stokes, Flecknell, and Richardson, 2009).
Additionally, the PHS policy covering all vertebrates is not applicable to any
private research institutions. Though there are methods of outside
assessment such as AALAC accreditation and state regulation requiring
stricter reporting, there are still many ways for animals to fall through the
reporting cracks. There is a need for a stronger force encouraging the
refinement and replacement of animal research methods within biomedical
research.
Researchers must have institutional incentives to assure that they are not
merely complying with regulations on animal care, but trying to be at the
cutting edge. Incentivizing the design of novel pain management techniques
for researchers to implement could provide a constant push to encourage ever
more ethical treatment of research animals.
"There are no gains, without pains"
-Benjamin Franklin, The Way to Wealth
III. Pain Sensing
Though pain sensing happens quite quickly, there is an extremely complex
procession of events happening between the time stimulus is sensed and
responded to. There is still work yet to be done before the scientific
community can even properly understand how pain perception functions both
in human as well as non-human animals (Twilley, 2018, Ingraham, 2018).
This chapter will focus on an overview of the nociceptive pathways that
initiate the pain sensation as well as methods that have been employed to
more closely understand how pain sensing is controlled in the body.
III.I Sodium Ion Channels
Pain signaling caused by an external stimulus is a process that begins at the
peripheral pain receptors and leads to the brain (Fig. 2). External nociceptors
are found in nerve endings within the epidermis, cornea, and mucosa. The
cell bodies of these peripheral nerve endings are primarily located in bundles
within the dorsal root ganglia. When a noxious stimulus is received by a
nociceptor, it activates the opening of a sodium ion channel specific to that
pain modality. This influx of sodium ions from the ion channel creates an
action potential that travels quickly through the myelinated A8-fibers and
enters the dorsal horn at the anterior of the spinal cord. The signal is then
sent from the first-order neuron though a synapses to the second order
neurons that cross from the anterior to the lateral spinothalamic tract. It
then ascends the spinothalamic tract to the thalamus, the section of the brain
that processes these stimuli. From there the signal can be translated into a
response at the site of initial nociception if determined appropriate.
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Figure 2: A sketch of the nociceptive pathway of nerve endings
Sodium ion channels were chosen as the area for modification for this project
because they are at the very beginning of pain sensation. Sodium ion
channels were first discovered in 1952 through Hodgkin and Huxley's voltage
clamp technique which elucidated action potentials across the neuronal
membranes of giant squid axons (Hodgkin and Huxley, 1952). These
foundational experiments showed that sodium ion channels have voltage-
dependent activation, rapid inactivation, and selective ion conductance.
Sodium ion channels are a family of highly conserved
z:
The family of voltage-gated sodium ion channels have been extensively
studied, with all but Na,1.5 being found within the central and peripheral
nervous system (Table 1).
Mammalian Sodium Channel a -Subunits
Type Gene Symbol
Nav1.1
Nav1.2
Nav1.3
Nav1.4
Nay1.5
Na,1.6
Nay1.7
Nav1.8
Nav1.9
SCN1a
SCN2a
SCN3a
SCN4a
SCN5a
SCN8a
SCN9a
SCN10a
SCN11a
Na, SCN7a, SCN6a
Chromosomal Location
Mouse 2 Human 2q24
Mouse 2 Human 2q23-24
Mouse 2 Human 2q24
Mouse 11 Human 17q23-25
Mouse 9 Human 3p2l
Mouse 15 Human 12q13
Mouse 2 Human 2q24
Mouse 9 Human 3p22-24
Mouse 9 Human 3p 2 1- 2 4
Mouse 2 Human 2q21-23
Primary Tissue
CNS neurons
CNS neurons
CNS neurons
SkM
Uninnervated SkM, heart
CNS neurons
PNS neurons
DRG neurons
DRG neurons
uterus, astrocytes,
hypothalamus
Table 1: List of Nav ion channel family. Adapted from (Catterall, 2000)
The structure of the a subunit of these channels is highly conserved, with the
proteins forming a selective pore for the sodium ions to travel through. Each
of the a subunits are around 260kDa and contain four homologous domains
(I-IV) as well as a reentrant loop within the transmembrane, with each
domain containing six a-helical transmembrane subunits (S1-6) (Fig. 3)
(Catterall, 2000). The fourth subunit (S4) is the voltage sensor, containing
hydrophobic amino acids with a positively charged amino acid in every
third. There is a P loop between S5 and S6 which acts as the selectivity filter
for the ion size, assuring that only the sodium ion enters. Inactivation of the
pore is controlled through a loop of hydrophobic amino acids between S6 of
domain III and S1 of domain IV, known as the IFM domain. IFM is a
reference to the three hydrophobic amino acids that make up the "hinge",
isoleucine, phenylalanine, and methionine. This is the tethered "hinge"
within the ion channel, allowing voltage-dependent movement through the
relative accessibility of key residues.
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Figure 3: Na, Channel Structure. a) 2-D structure of the a subunit of Na, ion channels, adapted from Catterall 2000
and b,c) 3-D structure of voltage-gated sodium ion channel cross-section and pore. adaptedfrom and Bagal et al. 2014
There are many members of the sodium-ion channel family implicated in
nociception, but this project is focused on common pain modalities
experienced by research animals. Therefore, the three ion channels that will
be analyzed for inducible ablation are Nay1.7, Na,1.6, and Na. (Table 2).
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A
Essential Sodium
Channel
Acute mechanic
pain
Inflammatory
hyperalgesia
ripheral Neuronal
Subpopulation
Classical nociceptive pain pathways
al Nav1.7 Sensory neurons
Nav1.7 Sensory neurons
Nociceptive pain pathways
Neuropathic cold
allodynia
Sympathetically
maintained pain
Nav1.7
Nav1.7
Sensory neurons
Sympathetic neurons
Atypical peripheral pain pathways
Oxaliplatin-evoked
allodynia
Nav1.6
Cancer-induced Nax
bone pain
Table 2: List of pain types in peripheral nerves. Adapted from Minett et al.. 2014
A-fiber associated
neurons
A-fiber associated
neurons
I.I.I Navl.7
The SCN9A gene encodes for the alpha subunit of the Na,1.7 voltage gated
ion channel, a pathway shown to be active following initial nociception within
sensory and sympathetic neurons as well as in olfactory neurons, pancreatic
tissue, and the hypothalamus (Nassar et aL., 2004). Initial experiments that
induced a global knockout of the gene found that the mice died soon after
birth. Upon further investigation, the role of the SCN9a within olfactory
pathways was implicated as the reason mice died, as destroying the gene
from birth resulted in mice that did not feed properly and died early on if not
individually fed (Nassar et aL., 2004, Gingras et aL., 2014).
Subsequent experiments employed localized knockouts in sensory or sensory
and sympathetic neurons for a more targeted approach at understanding
Nav1.7's role in pain perception (Minett et aL., 2012, 2014, 2015). These
experiments demonstrated that when the ion channel is knocked out in only
sensory neural tissue (Advillin), cold and mechanical allodynia pain
perception is still present. But when a sensory and sympathetic neural tissue
promoter (Wntl) was used, mechanosensory, inflammatory, thermal, and
some neuropathic pain perception are lost (Table 3). This is consistent with
the expression of Nav1.7 being in the peripheral nervous system, which
encompasses both the sensory and sympathetic neuronal populations.
Distinct Neuronal Subpopufations andMechanismsUnderlying Different Neuropathic Pain Mode Is
Deleted from
Nociceptors
Chronic Con
Injury
Cold M
Allodynia A
normal
Sensory lost lost
Neurons
Sympathetic
and sensory lost lost
neurons
Table 3: List of pain modes lost in Navi. 7. Adaptedfrom
striction
Spinal Nerve Transection
echanical Cold Mechanical
llodynia Allodynia Allodynia
normal normal normal
normal
lost
(Minett et al. 2014)
normal
lost
Oxaliplatin-Induced Pain
Cold Mechanical
Allodynia Allodynia
normal normal
normal
normal
normal
normal
Yet, a SCN9A knockout alone does not eliminate all pain states experienced
by mouse models used in research. Animals with loss-of-function mutations
in the peripheral nervous system are still susceptible to neuropathic pain,
such as that caused by oxaliplatin, cancer-associated pain, and acute cold
(Minett et aL, 2014).
111..11 Navl.6
Currently, there is very little understanding of neuropathic pain, and even
less about how to mitigate it (Hansson, 2003, Jose L. Ochoa, 2018). SCN8a,
which encodes for the Nav1.6 sodium ion channel, has been linked to both
chronic neuropathic pain and cold sensing in the central and peripheral
nervous system (Sittl et aL., 2012, Deuis et aL., 2013). As with many sodium
ion channels, global null mutations were an ineffective method to study this
Navl.7
gene. Global null mutations of the SCN8a gene caused ataxia, progressive
paralysis, and lethality by three weeks (Meisler et a]. 2001).
A floxed mouse model of the SCN8a gene was then made to further analyze
the gene while attempting to avoid the lethality associated with a null
mutation from birth (Levin and Meisler, 2004). The tissue-specific knockout
was done in cerebellar purkinje neurons and granule cells (Levin et a].,
2006). It is clear through these experiments that the floxed allele has
mitigated the lethality of the global mutation while allowing tissue-specific
knock-out analysis to be done. There has yet to be a published model showing
a conditional knockout of the SCN~a in either sensory or peripheral neurons.
As seen with SCN9a, there may be different pain types that are disrupted
with SCN~a, so tissue-specific promoters for both sensory or peripheral
neurons will be analyzed.
III.I.III Na.
Nax is an atypical sodium channel that is involved in osmoregulation through
extracellular sodium sensing (Gorter et a]. 2010). Expression within the
nervous system has been identified in in the Dorsal Root Ganglia astrocytes,
Schwann cells as well as the hypothalamus (Watanabe et a]. 2002, Garcia-
Villegas et a]. 2009). While little is known about this gene, RNAi knockdown
experiments have demonstrated that reducing SCN7a/Nax expression has
reversed some of the bone-cancer induced neuropathic pain (Ke et a]. 2012).
There has yet to be a published floxed model of SCN7a, or much analysis on
tissue-specific knock-outs thereof. Oncological studies are a major source of
animal suffering, which puts blocking pain resulting from tumor growth and
chemotherapy-induced neuropathy as a high priority.
There is much to be learned about attempting inducible tissue-specific
disruptions of SCN9a, SCN8a, SCN7a individually, particularly for further
elucidation on chronic and cancer-induced neuropathic pain as well as
crossing those that show promise to each other, could begin to address the
multiple chronic pain types that arise in animal models during
experimentation.
III.II Tissue-Specific Expression
When designing a transgenic system that requires precise localization and
expression of a protein, the key is finding the right promoter. This is
important primarily to assure that your protein of interest is restricted to be
expressed in the correct tissue. Additionally, it is important for the level of
expression to be appropriate to the protein that you want to be expressing in
a given region. This section will discuss the rationale behind the tissue-
specific promoters that were chosen for this project as it pertains to the
desired recombinase and nuclease expression.
While many of these nociceptor genes are primarily expressed in sensory
cells, they serve other functions as well. The peripheral nervous system is the
area of broad interest, as it is where the nociceptors are primarily localized.
But within the peripheral nervous system there are different populations of
neuronal cells that can be targeted.
III.II.I Advillin Promoter
The standard promoter that had been used within the field of nociception has
been the Advillin promoter (Hasegawa et a]. 2007). Advillin is a gene found
primarily in peripheral sensory neurons and is a member of the
gelsolin/villin family of actin regulatory proteins (Marks et a]. 1998). As seen
in the previous section, many of the Nav channels are expressed within DRG
populations, which is where sensory neurons can be found. Therefore, it is a
good strategy to study a tissue-specific knock-out of a Nav channel using the
Advillin sensory neuron-restricted promoter.
Furthermore, an inducible Advillin Cre-ERT2 system has already been made
and characterized (Lau et a]. 2011). This model can be purchased and mated
with the floxed mouse models being developed to understand the pain
phenotype associated with the SCN8a and SCN7a genes, neither of which
have any published results using this promoter.
III.II.II Wntl Promoter
The Wnt family of genes are well characterized for their expression within
the brain and nervous system (Fig.4). Specific attention has been paid to its
uses within understanding brain development, including midbrain
development and neural crest migration. The Wntl gene in particular has a
consistent expression throughout development, so a Wntl-Cre mouse model
was made in the 1990's to be mated with a lacZ reporter strain. (Danielian et
a]. 1997).
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Figure 4: I'ni expression patterns. Adapled j5iom (Oliva. Montecinos-Oliva. and Inestrosa 2018)
Unfortunately, ectopic expression of the Cre made it an unattractive option
for use because of midbrain enlargement. The model was successfully
modified to limit the ectopic expression found within the system (Lewis et al.
2013, 1). This promoter has been shown to give the most robust ablation of
pain perception for the SCN9a floxed models. Because SCN8a is restricted to
the CNS neurons, it will be interesting to see whether there is a difference in
the pain using the Wntl model in comparison to trying a promoter restricted
to the CNS. Similarly, SCN7a has not been selectively knocked out in
different neuronal populations. Therefore, it will be interesting to see how the
addition of sympathetic neuronal expression will impact the pain perception
of the mouse model.
"...endless forms most beautiful and most wonderful have
been, and are being evolved"
-Preface, The Origin of Species, Charles Darwin
IV. Inducible Pain-Free Mouse Model
When designing this system, it is important to note that this was not
intended to be novel in technique, but in intent. The experiments done in the
Wood Lab were an important foundation used to steer the direction of the
design of this project. Studies have shown that sensory and sympathetic pain
from birth has impacts on the general well-being of animals due to a failure
to learn self-preservation behaviors. For example, humans born without
functional SCN9A often incur injuries such as broken bones and chewed
tongues due to the failure to acquire pain avoidance strategies early in life
(Weiss et a]., 2011) (Drenth and Waxman, 2007). Therefore, we designed the
system so that mice will be raised with pain perception intact to learn pain
avoidance and decrease chances of accidental self-inflicted injuries. Then,
before with pain perception ideally eliminated just before the mice are
scheduled for an experiment.
When considering which inducer to use for the system, it was important to
consider how it will impact the system's overall usability as a research model.
A promoter induced by a tetracycline-class molecule seemed to be the ideal
promoter system, because there are a few tetracycline-class molecules that
have been shown to be biologically inert, including anhydrotetracycline and
4-epidoxycycline(Nelis and De Leenheer, 1981). This assures that induction
of the system will had minimal impact on experimental conditions and
results. However, some reports have indicated that induction with
tetracycline-class promoters does not function in all neurons due to silencing
of the Tet-responsive element promoter (Qin et aL., 2010).
Consequently, an orthogonal system proven to be effectively expressed within
neurons was developed as well. 4-hydrotamoxifen class promoters have
already been published to function within sympathetic and sensory neurons
(Minett et a]. 2012). Because this is a hormone-associated pathway, it might
not be best for all research types. The hope was that between the two systems
there would be sufficient options for researchers to try.
Finally, considering conditions associated with animal experimentation, is
important to consider the genetic background of the system in order to assure
that the mouse will be useful for a broad range of research uses. C57B1/6 mice
have been estimated to comprise -50-80% of all mice used in medical
research and are reportedly unusually sensitive to pain while being resistant
to common analgesics (Mogil et a]., 1999). Therefore, we chose this genetic
background for the initial inducible pain-free system design ("C57BL/6",
2016).
V.I Early Designs
The system was initially designed to be made via embryonic stem cell
selection. Three different system designs were considered for gene disruption
in an attempt to understand which model would provide the best special and
temporal control of the gene disruption. I will describe these initial designs
because they were not abandoned due to flaws in the system, but due to
switching methods of integration and simplifying experimentation.
V.I.I Cre-ERT2 Inducible Mouse
This mouse model will be identical to previous Cre-based SCN9A knockout
lines save that Cre will be inducible in Wntl-expressing cells upon delivering
a 4-hydrotamoxifan class molecule rather than expressed in the peripheral
nervous system from birth (Minett et aL. 2012, 2015). The DNA cassette was
designed with modified lox sites to be integrated into the HPRT locus, a
common integration site for ES cell selection, using a modified targeting
vector with complimentary lox sites. The system is designed such that once
the Wntl-CreERT2 in integrated, the lox sites will be dead to assure that any
future Cre expression will not impact the cassette (Fig. 5).
Figure 5: HPRT Integration. A depiction of the Wntl cassettes integrating into the modified HPRT locus targeting
vector via lox sites
To maximize efficiency, loxP sites will be inserted around exons 14 and 15 of
the mouse SCN9A gene encoding the Nav1.7 ion channel. Single-guide RNAs
(sgRNAs) will direct Cas9 to cut upstream of the targeted exons, leading to
insertion of a repair template with the floxed exons and an FRT-site flanked
neo/kan selectable marker (Fig. 6). After selection, the neo/kan selectable
marker will then be removed using FLP recombinase(Buchholz, Angrand,
and Stewart 1998) A similar approach will be employed to flox key exons in
SCN7a and SCN8a.
After cells have gone through rounds of selection for integration of both the
Cre recombinase and the floxed exons, induction of the generated mice by a 4-
hydrotamoxifan class molecule should result in Cre activity and initiate the
gene knockouts in both sensory and sympathetic neurons (Fig.7).
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Figure 6: Floxed SCN9a. a) The SCN9A gene will be recoded using CRISPRICas9 gene editing to place lox sites
around exons 14,15, and 16 as well as a neo/kan selectable marker for east of ES cell selection. b) After the cells are
selected for the tioxed exon repair template, the neolkan selectable marker will be removed using a flippase.
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Figure 7: Cre ERT2. a) The Cre-ER T2 construct within the tissue-specific Wntl promoter incorporated into the
HPRTlocus b) Once 4-hydrotamoxifenis introduced into the system, Cre recombinase will be expressed in peripheral
nervous tissue and will excise exons of the SCN9A gene.
V.I.I Cas9-ERT2 Inducible Mouse
This mouse model will employ the Cas9 endonuclease and an array of
CRISPR sgRNAs targeting key exons within SCN9a under the control of a
ERT2 inducer within Wntl-expressing cells to disrupt target genes in a
tissue-specific manner. The cassette will be integrated into the HPRT locus
using the same modified targeting vector discussed previously. (Fig. 8a).
Once integrated, induction of the generated mice by a 4-hydrotamoxifan class
molecule should result in expression of the Cas9 endonuclease which will
complex with expressed sgRNAs and direct SCN9a gene ablation in both
sensory and sympathetic neurons of mice (Fig. 8b).
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Figure 8: Cas9-ERT2. a) The Cas9-ERT2 construct and anti-SCN9A array within the tissue-specific Wntl promoter
incorporated into the HPRT locus b) Once 4-hydrotamoxifenis introduced into the system, Cas9 endonuclease and
sgRNAs will be expressed in peripheral nervous tissue and will cut key exons in SCN9A.
V.I.11I Cas9-Tetracyclin Inducible Mouse
Similar to the previous model, this mouse model will employ a Cas9
endonuclease and the same CRISPR sgRNA array targeting SCN9a exons to
ablate the target genes. The difference lies in the Cas9 and method of
activation, with this system employing a split Cas9 where the N and C
terminus will be separately expressing and self-assemble upon activation of a
tetracycline-responsive activator (Zetsche, Volz, and Zhang 2015).
A TRE3G-bidirectional promoter along with the SCN9a CRISPR array and
an FRT-flanked neo/kan selectable marker will be inserted in the ROSA26
locus. This will be done using a modified targeting vector similar to what was
designed for the HPRT locus, which has previously been used for tet-
dependent gene expression (Rideout et aL. 2000). The reverse tetracycline-
controlled transactivator (rtTA) required for TRE3G expression in the
presence of tetracycline will be placed under the Wntl promoter along with
the CRISPR array using the modified HPRT targeting vector (Fig. 9a).
Once integrated, induction of the system with a doxycycine-class compound
is fed to the mouse, rtTA expression will activate the TRE3G promoter which
will express both halves of the Cas9 endonuclease. These will self-assemble
into an active nuclease, localize with sgRNAs, and direct SCN9a gene
ablation in both sensory and sympathetic neurons of mice (Fig. 9b).
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Figure 9: Split-Cas rtTA. a) The rITA construct within the tissue-specific Wntl promoter incorporated into the HPRT
locus b) The split Cas system under TRE3G bidirectional tet promoter with the anti-SCN9A array and a neo/kan
selectable marker flanked by FRT sites incorporated into the ROSA26 locus c) Once 4-hydrotamoxt/enis introduced
into the system. Cas9 endonuclease and sgRNAs will be expressed in peripheral nervous tissue and will cut the exons of
the SCN9A gene and break the Nav1. 7 ion channel.
V.I Final Designs
Upon further consideration of the goals of the project, we decided that using
CRISPR gene editing for integrating of the DNA constructs into mice through
pronuclear injection (PNI) over embryonic stem cells selection methods (Horii
et al. 2014) (Fig. 10). In a CRISPR PNI, a fertilized zygote is isolated before
the first genetic doubling and microinjected with a cocktail of endonuclease
pre-complexed with the RNA guide as well as the repair template. This
switch in methods allowed for less time lost in breeding.
With ES cell selection, most integrations will produce mosaic animals due to
cell cleavage. This requires more breeding to get pure mice and also creates a
risk of an integration that is not passed to the germ cells. However, there is
typically no instances of mosaicism being found for CRISPR PNI when pre-
complexed endonuclease injected. Therefore, all founders that have the
correct integration will be ready to be bred with the additional integrations
needed for the system to function.
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Figure 10: Pronuclear Injection ( Wilev Press Images, 2012
After we decided to switch to a CRISPR PNI procedure, the DNA construct
designs needed modification to accommodate this new method. Firstly, there
was no antibiotic selection needed for this method. Secondly, designs were
modified to give asymmetric homology to the homology arm, which has been
shown to increase the chances of proper integration of the construct (Wang et
al. 2018). Because each mouse line would need to be made, genotyped, and
bred, we decided that making the three designs discussed above in parallel
would be difficult.
We chose the Cre-ERT2 inducible mouse with floxed exons as the first model
to be made, because the Wntl promoter has already been proven to work in
an non-inducible fashion and the ERT2 inducer has been proven to work in a
sensory neuron-restricted context (Lau et aL. 2011, Minett et aL. 2012). We
will therefore develop a Wntl Cre-ERT2 mouse strain and floxed strains of
mice for all of the sodium ion channels of interest. When the system is
induced through a 4-HT class molecule, the floxed genes will be excised,
which will cause a loss-of-function mutation for the gene going forward
(Fig. 11).
The Cas9-ERT2 and Split Cas9 mice will be designed and produced, in that
order, if the Cre-ERT2 mouse does not produce the desired pain-free
phenotype. Primers and full plasmid sequences the final designs can be found
in Appendix I.
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Figure 11: Wntl Cre-ERT2 system. When a 4HT-class molecule is fed to the mouse (top), it will induce a
recombination at the lox sites which will delete exons 14 and 15 from the gene (bottom).
V.II.I Wntl Cre-ERT2 Construct
Once we decided on using CRISPR PNI, the initial Wntl Cre-ERT2 construct
design was modified because there is an existing mouse model with Cre
recombinase under the Wntl promoter (Lewis et aL. 2013). This mouse model
is kept in the Jackson Laboratory mouse facility under B6 Wntl-Cre2 (Jax
#022501).
The exact sequence of the initial Cre recombinase construct was obtained
from Prof. Jeffrey Bush to be ordered as gblocks for homology arms. An ERT2
sequence was isolated from the pCAG Cre-ERT2 plasmid (Addgene #14797)
to be added between the Cre recombinase sequence and terminator. The
plasmid, named "DM Analgesia," can be seen below, along with images of the
PCR products and final assembled plasmid. More information on the design
can be seen in Appendix I (Fig.12-13, Table 4).
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Figure 12: DM Analgesia plasmid design
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Figure 13: ERT2 insertion. The guides cut between the Cre recombinase and the terminator and the repair template
contains the ERT2 addition.
The transgenic facility at Boston Children's Hospital performed the PNI
along with four RNA guides pre-complexed with Cas9 before injection for
construct insertion. The injection took place on August 13, 2018 and 22 pups
were born from the litter. The mice will be genotyped and then bred with the
floxed mouse line discussed below.
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V.II.11 Floxed Ion Channel Constructs
Nav1.7
We designed the floxed SCN9a construct to delete exons that are confirmed to
disrupt function of the gene. Based on initial work by the Wood lab, we chose
to place loxP sites around exon 14 and 15 (Minett et al. 2012). Lox sites were
place far enough from the spice regions within the introns so as to not disturb
function of the gene before the system is induced. We used mouse genomic
DNA from a C57B1/6 background to design this constructs and lox sites were
added with primers.
The transgenic facility at Boston Children's Hospital performed the PNI
along with four RNA guides pre-complexed with Cas9 before injection for
construct insertion. The injection took place on May 25, 2018 and 31 pups
were born from the litter. None of the mice were confirmed to have integrated
the template with the lox sites. Another guide has been ordered and another
round of CRISPR PNI is scheduled for the near future.
The plasmid, "floxed SCN9a," can be seen below, along with images of the
PCR products and final assembled plasmid. More information on the design
can be seen in Appendix I (Fig. 14-15, Table 5).
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Figure 14: floxed SCN9a plasmid design
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Figure 15: SCN9a loxP insertion. The guides cut proceeding exon 14 and following exon 15, with the repair template
containing the loxP sites
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We had made preliminary designs to make a floxed mouse for SCN8a encoding for the
Na, 1.6 ion channel. But upon further investigation we discovered that the Meisler lab still
has a colony of the floxed SCN8a mouse that they generated for their studies (Levin and
Meisler 2004). We hope to acquire these mice upon further discussions with the lab to
mate with the inducible Cre strains.
Na.
There is no floxed model for Nax that could be found. Therefore, similar to SCN9a, we
designed placed lox sites far enough from the spice regions within the introns so
as to not disturb function of the gene before the system is induced. We used
mouse genomic DNA from a C57B1/6 background to design this constructs
and lox sites were added with primers.
The transgenic facility at Boston Children's Hospital has received the guides
and plasmid for this construct and the CRISPR PNI is scheduled for the near
future.
The plasmid, "floxed SCN7a," can be seen below, along with images of the
PCR products. More information on the design can be seen in Appendix I
(Fig.16-17, Table 6).
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Figure 16: floxed SCN7a plasmid design
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Figure 17: SCN7a loxP insertion. The guides cut proceeding and following exon 15, with the repair template
containing the loxP sites
"This subtle matching of procedure to species, and species
in turn to objectives, is more significant than appears at
first sight for the humanity of technique."
- The Principles of Humane Experimental Technique, W.M.S. Russell and
R.L. Burch
V. IACUC Survey
To better understand the broader bioethical implications of the pain-free
mouse system, as well as its potential adoption by the research community,
we designed a survey for IACUC (The Institutional Animal Care and Use
Committee) members around the country. The survey seeks to clarify how the
framework established by the USDA and OLAW impacts the decisions of
IACUC members when approving an animal protocol. There was particular
emphasis on understanding the appropriate pain category the animal would
be placed in when being reported on a protocol. Additionally, we gathered
more information on understanding the level of characterization needed on
the system such that IACUC members would feel comfortable approving or
even recommending it when researchers submit protocols. The full set of
questions for the survey along with the survey logic can be found in Appendix
II.
VI.I Survey Approval
Given that this survey was intended to be sent to 'human subjects,' it
required review by MIT's Institutional Review Board, called the Committee
on the Use of Humans as Experimental Subjects (COUHES). Because the
survey posed was anonymous and that did not ask any questions that would
reveal sensitive material from participants, the survey was submitted to
COUHES requesting an exemption. The request was granted under the
conditions that survey taker digitally content to participating in the survey
and being notified that they can stop the survey at any time without penalty.
VI.II Survey Development
The survey started as a conversation between myself and Prof. Peter Singer
in mid-August of 2017. We had discussed the possible negative outcomes that
could arise from the inducible pain-free mouse model outlined in this thesis.
He had brought up the possibility of this mouse model being used as a
loophole by researchers in order to perform painful research that may
otherwise not be approved by an IACUC. It is clear that there is a level of
interpretation by individual IACUC members in the process of interpreting
some of the regulation and recommendations in place (Tannenbaum and
Bennett 2015). Therefore, in an effort to explore the possible negative
impacts of the model, I created a survey for IACUC members aimed at
understanding how the mouse model might be seen within the USDA's
regulatory framework as well as the opinion of the members themselves
towards the idea in relation to how things are currently being done.
VI.II.I IACUC Metadata
According to the OLAW requirements, there must be at least 5 members on
an IACUC committee, with at least one in each of the following categories:
veterinarian, practicing scientist that is experienced in animal research,
designated non-scientist affiliated with the institution, and non-
institutionally affiliated member that represents the community the
institution resides within. But there is currently no public accounting of how
many members any given IACUC has.
Similarly, the OLAW provides two different methods for reviewing protocols,
full committee review or designated committee review. In the case of a full
committee review, every protocol is discussed and decided upon by all of the
members at their meetings in the presence of a quorum. In the case of a
designated committee review, the protocol is given to a qualified committee
member who is designated by the chair to review and decide upon the
protocol with the exception that a disapproval would require a full committee
review. There is similarly no accounting for which method of review each
IACUC implements.
The first part of the survey therefore collected the role of the survey taker,
the number of IACUC members on the committee they are affiliated with,
and the preferred method of analysis by their committee. Additionally, this is
informative material for the IACUC community at large to learn about itself
and will be presented back to the community for their use.
VI.II.II Institutional Animal Experimentation and Pain
The next section focused on clarifying the current state of painful animal
experimentation within these institutions. If there is not much
experimentation that uses Category D or Category E animals, or if the
IACUC members feel that pain is being properly managed within the
protocols they approve, there is not much grounds with which to propose a
new system a problem that does not exist. To review, Category D animals are
classified as animals subjected to potentially painful or stressful procedures
for which they receive appropriate anesthetics, analgesics and/or tranquilizer
drugs, and Category E animals are classified as animal use activities that
involve accompanying pain or distress to the animals and for which
appropriate anesthetic, analgesic, tranquilizing drugs or other methods for
relieving pain or distress are not used or delayed for scientific purposes.
Scientific justification has to be provided.
The questions first probed how many animals per month on protocols
submitted to the IACUC were Category D or Category E animals. Additional
questions on whether new refinement strategies were needed within
experimentation using Category D & E animals as well as whether the
survey taker felt that pain was being properly managed in experiments
involving Category D animals (the answer is obviously no for Category E
animals by definition) was determined.
VI.II.III The Inducible Pain-free System
After determining whether there is a systemic need for new refinement
strategies, questions regarding a possible inducible pain-free system were
presented. Questions on whether an inducible pain-free system could be
considered a "refinement" strategy for animal experimentation, whether the
animals would be categorized in the same way that an animal receiving
analgesics or anesthetics would be, how many peer reviewed papers on the
system would be sufficient for the committee members to feel comfortable
approving, recommending, or even requiring the use of the modified animals.
At the end of the survey, a long-form response was available for survey
takers to respond with final comments or recommendations regarding the
survey and the proposed system.
VI.III Survey Results
Almost all of the questions presented in the survey were multiple choice to
minimize the grey areas that form when open responses are collected. I will
first present the data from the survey, and then discuss the long-form
responses and methods for improvement for the next iteration of the survey
and possibly the project as a whole.
There were 48 survey responders, with 43 responding to any question past
the initial consent form and about 36 respondents that completed the whole
survey. Below is an in-depth analysis of the survey results. The full survey
results can be seen in Appendix II.
VI.III.I IACUC Metadata Results
Question 3: Role on IACUC
Of all of the possible roles that the respondents could be, about 35% were
IACUC administrators. IACUC Administrators are not part of the IACUC
committee, they are involved in most aspects of IACUC protocol review and
approval, and are therefore a huge resource of information with regard to
IACUC statistics and committee member sentiments. About equal numbers
of those who identify as the Veterinarian or Practicing scientist responded to
the quiz, each making up about 20% of the respondents. Chairpersons made
up about 14% of respondents. The "Other" category had four responses, one
who identified as "Statistician", one as "Compliance", one as "Coordinator,"
and the final one as "and chair."
Question 3: Role on IACUC:
Answer %7
Veterinarian 20.93%
Non-scientist 2.33%
Non-affiliated member (representing 0.00%
community)
Practicing scientist experienced in 18.60%
animal research
Chairperson 13.95%
Administrator 34.88%
Other 9.30%
Table 7: Response to Role within the IACUC
Question 4: IACUC size
There was a range from 5-30 members on an IACUC reported, with an
average number of members per committee found to be 13 members.
Question 5: Protocol Review Method
In response to the question on the preferred method of protocol review, it is
about split between those who use both methods and those who mainly or
only choose one. Full committee review seems to be preferred over designated
member review, with further analysis showing that designated member
review or both methods being more likely to be chosen by a respondent whose
IACUC has an above average number of members.
Question 5: Protocol Review Method
Answer %
Designated Member Review (mainly or 20.93%
only)
Full Committee Review (mainly or 32.56%
only)
Both depending on circumstances 46.51%
Table 8: Method of protocol review
VI.III.II Institutional Animal Experimentation and Pain Results
Question 6 and 7:
In response to the questions regarding the number of Category D and E
animals investigators submit for review in their experimental protocols, it is
clear that protocols involving category D animals are very common. Almost
half of respondents indicated that somewhere between 60% to over 80% of
protocols they receive involve category D animals, meaning the vast majority
of all animal experiments run involve some painful event that the
investigator is typically required to mitigate with analgesics or anesthetics.
There was a comparative lack in proposed Category E animals used. Over
two thirds of respondents indicated that less than 20% of protocols involve
category E animals. This is unsurprising, because experiments that are
approved with Category E animals typically require extensive reasoning for
their pain category choice due of the confirmed pain and distressed the
animal will experience. But it should be emphasized that even a few animals
in Category E is too many. If there is a method of recapitulating the
phenotype needed during painful experiments, typically inflammatory,
W
without needing the animal to be experiencing the full extent of the pain then
steps should be taken to reach that.
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Question 8:
In response to the question regarding whether there is a need for further
refinement within experimentation around Category D and E animals, 80%
of respondents agreed. It is a regulatory requirement for IACUCs to find
ways to avoid experimentation on animals as well as more refined
experimentation of the experiments cannot be avoided, but it is nonetheless
an important confirmation that there is always further work that needs to be
done within experimental refinement as long as animal experimentation
continues.
Answer 4/0
Yes 79.49%
-No 12.82%
Other 7.69%
Table 10: Further refinement needed in research
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Question 9:
In response to whether the respondent feels there is effective main
management in the experiments being done under their IACUC, there was a
mixed response. About two thirds of the respondents indicated that the issue
of pain is moderate, with the intention of controlling the pain as best as
institutionally possible. It is important to note that almost one third of
respondents felt that the issue of pain was well managed, while about 12%
responded that there was no need for further refinement.
Question 9: Rating animal pain in Category D animal
experiments institutionally
Answer %
Low (Either procedures are not painful or the 32.43%
pain is well controlled.)
Moderate (Painful procedures are limited, and 62.16%
pain is controlled the best we can, but animals do
sometimes experience some pain.)
High (Procedures are very painful and controlling 5.41%
pain is a challenge.)
Table I i: Animal pain in Category D animals
It is interesting to note that 12 respondents chose that pain was well
managed in their institution, only 5 responded that they did not feel there
was a need for refinement within Category D&E research. It is clear from
this that even if pain management seems to be well established, highlighting
that there is always a need for further refinement within experimental
practices.
VI.III.II The Inducible Pain-free System Results
Question 10:
In response to whether an inducible pain-free mouse model would be
considered a method of "refinement" within the research landscape, most
respondents agreed that it would be an appropriate method of refinement.
This indicates that the proposed mouse model would be seen by IACUCs as
an improvement in experimental technique with regards to animal welfare.
Answer
Yes 86.11%
13.89%No
Total 100%
Table 12: Inducible pain-free mouse as refinemeni
Question 11
In response to whether the mouse model would be classified similar to an
analgesic or anesthetic, almost three quarters of respondents said that they
would classify it similarly. Within the free response section there were
respondents that noted that they would have given a different response had
the question be worded to compare it only to an analgesic, not an anesthetic.
Anesthesia is used as a method of animal restraint and therefore the pain-
free model would not be sufficient in replacing anesthesia. It is possible there
were other respondents who felt similarly.
Answer %
Yes 73.53%
No 26.47%
Total 100%
Table 13: Inducible pain-free mouse as an analgesic
Question 12-14
In response to whether they would be willing to approve the use of Category
D and Category E animals, it seems that preliminarily almost 90% of
respondents would approve Category D and over 75% would approve the use
of Category E experiments. This is useful to consider when designing the
initial characterization of the system.
Answer % Answer %
Yes 88.89% Yes 77.14%
No
Total
11.11% No
100% Total
Table 14: Ising Categorv' D & E animals for model validation
22.86%
100%
In response to how many peer-reviewed publications the respondents would
like to review in order to feel comfortable approving the model being used for
a similar application, a bit over half indicated that 5+ papers would be
required. This too is important to consider when designing the tests for
characterizing relevant pain modes that may be be best suited for this mouse
model.
Question 14: Number of Peer-reviewed studies needed for validation
51.43%
2.86%
37.14%
8.57%
01 *2 U3 E4 5+
Table 15: Peer-reviewed studies needed for model approval
Question 15
Finally, the in response to whether the IACUC members would require the
use of the the inducible pain-free model given enough characterization
indicated that, as with most refinement strategies, this model could be a
recommendation made by the IACUC member to the investigator. One
respondent further elaborated in the free response section that they do not
feel it is their position to tell an investigator which animal model to use.
Another noted that labs generate or already have strains recapitulating the
biological conditions they are trying to study. Trying to encourage the use of
the inducible pain-free mouse model on top of the other requirements of could
be a big ask for researchers.
Question 15: With enough characterization, would you require the
use of this model in research studies?
Answer %
Yes 16.67%
Yes, if the investigators cannot use 16.67%
traditional analgesics or anesthesia
No, but I could recommend it as a 63.89%
further refinement strategy
No 2.78%
Table 16: Inducible pain-free mouse as a requirement
VI.III.IV Free Response Results
Allowing respondents to answer each question of the survey in their own
words would make the results of this survey difficult to analyze, which is why
multiple choice was used for many of the responses. But getting the opinions
of individual respondents was important both to understand how to improve
any further interactions with IACUC members as well as to give the
respondents a place to further clarify or qualify their multiple choice
responses. All of the responses can be seen in Appendix II, but I will highlight
some of the responses that I found to be particularly helpful.
Firstly, there were quite a few very positive responses to the system While it
is possible that this is not indicative of the entire IACUC community, but it is
encouraging nonetheless.
Many respondents indicated concern over the wellbeing of the inducible pain-
free mouse because pain-free phenotypes have been a fitness disadvantage to
mice who do not learn critical pain-avoidance habits. Similarly, there were
those who noted that while an animal may not feel physical pain, there is still
an ability for those animals to be in a state of distress. The goal of this
system is to increase the overall wellbeing of these animals, so the fitness
and distress levels are both components on the induced mice that will be
characterized in comparison to unindicted mice as well as wild type mice.
Additionally, further studies can be done on how inducing the system at
various times in mouse development might impact their overall fitness, which
could indicate at which stages the mice are most likely to learning pain
avoidance habits.
One respondent mentioned that anesthesia is more commonly administered
to animals to immobilize the anima during experimented than to reduce pain
during a procedure. Therefore, it was suggested that this system only be
proposed as an alternative to analgesics. This comment is important to
consider, as I had not known that this was a common method of animal
restraint. Understanding anesthetics role in animal experimentation can be
further researched to determine whether this system should be aimed to
replace only analgesics in comparison to also considering it an effective
alternative for some anesthetic purposes.
Many other respondents noted the complexity inherent in many animal
model systems. Factors involving strain, sex, and specific pain phenotypes or
pathologies are all factors that have to be seriously considered in the context
of characterization of the pain-free mouse system as well as any eventual
implementation thereof. Therefore, it may be in the best interest to
understand which areas of research are best suited for this inducible pain-
free model and work with investigators in those fields to assure that the
system design and characterization is in line with any specifications they
may have.
"Our work is never over"
- Daft Punk, Harder, Better, Faster, Stronger
VI. Discussion and Next Steps
VII.II Discussion
This thesis presented a holistic approach on understanding animal suffering
through the lens of philosophy, history, and biology. It proposed an
optimization to the current methods of painful animal experimentations used
by researchers in the form of an inducible pain-free mouse model. Finally, it
analyzed the regulatory landscape the model would exist within and assured
that this model is considered both necessary and needed as a method of
further refinement within animal research. Below are the next steps for
characterizing and implementing the inducible pain-free mouse project will
be outlined.
VII.II Mouse Model Evaluation
Firstly, we will genotype the mouse strains that are being generated and
breed to homozygosity in the case of the floxed SCN9a gene. Genotyping will
be done by using PCR, subcloning the products, and sequencing for
confirmation of insert. Once this is complete, we will mate the Wntl Cre-
ERT2 mouse with the floxed mouse in order to produce a mouse containing
both genetic edits. After further genotyping for confirmation of the final
model, we will perform testing the pain threshold of the mice. In
collaboration with the Woolf Lab at Boston Children's Hospital / Harvard
Medical School, we will set up blinded tests to determine the pain perception
capabilities of our transgenic mice in comparison to wild-type littermate
control mice. We will also compare the the pain perception capabilities of the
transgenic mice with and without induction. The tests that will be performed
on the mice can be seen in in Table 17.
Pain Testing
Pain Type
high-threshold
mechanical sensitivity
heat sensitivity
inflammatory pain,
mechanical allodynia
cold allodynia
neuropathic pain
oxaliplatin-induced pain
cancer-induced bone pain
Test
pinched with calibrated forceps
radiant and contact heat latencies will be
administered to the mice.
unilateral, intraplantar or intraknee injection of
complete Freund's adjuvant
thresholds will be determined using von Frey
filaments
acetone will be evaporated on the paw of the mice
surgically induced spare nerve injury and then be
tested for mechanical and thermal related
neuropathic pain (SNI) post-surgery
mice will receive oxaliplatin intravenously by tail
vein injection
metastatic bone pain cancer mice will receive an
intrafemoral injection of LL/2 lung carcinoma cells
and all spontaneous movement-evoked pain
response will be measured to evaluate pain
behavior.
Table 17: Pain Testing
Additional tests will be conducted to understand the quantify the quality of
life of the mice with and without the system being induced. This will be done
primarily by monitoring the extent of nesting and the grooming habits of the
mice.
If initial characterization of the inducible pain-free system performs well, we
will characterize the pain states of mouse models that have multiple sodium
ion channels floxed to better understand how to mitigate multiple pain
states. Additionally, we hope to partner with those working in fields where
mice experience chronic neuropathic pain, such as many oncological models,
and understand how our model can be best adopted for their research.
VI.III IACUC Survey
In the future, the survey will be sent out to the PRIM&R community to try
and gather more responses to the survey. This will be done by a posting on
Ampersand, the PRIM&R blog. This will allow for a larger response and give
a clearer idea of how the model is perceived by the regulatory system.
With respect to representation within the survey, there is certainly work to
be done. There were almost no responses to the survey that represented the
non-scientist or non-affiliated members of the IACUC. It would be useful in
understanding what about they survey deterred these members from initially
participating. Their opinion on animal suffering as well as current and future
methods of refinement in animal experimentation is important to the success
of this project, and should be looked at further.
Furthermore, there were many points brought up in the responses at the end
of the survey that would be good to follow up on. It is yet to be decided
whether this will be done through an additional survey or through contacting
members of an IACUC or the USDA's OLAW, or both, to clarify important
points.
Finally, it would be useful to converge on a particular pain modality and field
of research that is best suited for one of these models. The model can then be
further characterized to the specifications of the particular field in addition to
the IACUC requirements to assure the model can be implemented as soon as
possible.
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Appendix I
DM Analgesia
Full sequence can be found at (https://benchling.com/s/seq-
kXJcjWCKCMaPqfoEkGOQ)
Below is the list of primers used for DM Analgesia, the plasmid that was designed to add
ERT2 control to the Wntl Cre recombinase mouse.
# Primer Tm Info
DN354 ACCTCACACCATGCUctcgagccatctgctg
gag
DN355 gctgatcagcgagctctagaagctttgtgactatcaag
ctgtggcaggga
DN356 tagtcacaaagcttctagagctcgctgatcagctcgac
tgtgccttctagttgc
DN357 AGGCTTTTGACTTGGCUgagggctttctge
tcttttcttcttccct
DN364 cggAGGCTTTTGACTTGGCTgagggctttc
tgctcttttcttcttccc
DN365 tcatagggaagaagaaaagagcagaaagccctcAG
CCAAGTCAAAAGCCTc
DN366 tggcaggatgaaAGTTCCTCCTGGGCTgac
ttcag
DN381 AGCCCAGGAGGAACUgacggttagcctgtc
agc
DN382 AGCATGGTGTGAGGUcgagtaattggtaga
attcacgeg
DN383 AGCCAAGTCAAAAGCCUccgaccggaggc
tttt
68.7
69.91
FWD USER primer
ERT2
REV OEPCR for ERT2
69.4 FWD OEPCR 3' with
ERT2 hom new
69 REV USER wnt 3'
homology new
69.6 REV OEPCR for wnt 3'
homology new
68.6 FWD OEPCR for DM
BB with 3' hom
67.4 REV primer for DM BB
OEPCR (DN365)
69.2 FWD USER primer
wntcre_5_2
66.3 REV USER primer
wntcre_5_2 gblock
68.5 FWD USER DM BB
primer DM analgesia
Below are the PCR settings for the DNA fragments amplified for DM
Analgesia assembly. All PCRs were carried out using Phusion U Hot Start
Mastermix.
1 DM ti1
with
OEPCR
hom
2 Wntl-Cre
5'
homology
3 ERT2
with
OEPCR
4 Wntl-Cre
3,
OEPCR
hom
5 DMBB+
5'
6 ERT2 + 3'
UN365 DN366 DM 58 68
anything
DN381 DN382 Wntl- 55 67.9
DN354 DN355
DN356 DN364
DN383 DN382
DN354 DN357
Cre 5'
homology
gblock
pCAG
Cre
ERT2
Wnt1-
Cre 3'
homology
gblock
PCR 1+
PCR 2
PCR
3+PCR 4
56
1 mm
1 min
68 1 min
57 69 1 min
52 67 2 min
53 69 1 min
15 sec
All of these PCRs were two temperature PCRs, where the first five cycles are
at the first temperature and the last twenty-five cycles at the second
temperature. Below is the thermocycler program:
Stage 1 Stage 2 Stage 3 Stage 4
98C
30 sec
98 C
10 sec
T1
15 sec
72C
Ext
98C
10 see
T2
15 sec
72C
Ext
72C
7 min
Below are the g-block ordered from IDT for 5' and 3' homology arm to the B6
Wntl-Cre2 mouse (Jax #022501) with slight modifications made to destroy
the Cas9 PAM sites used to integrate the construct:
B6 Wntl-Cre 5' homology gblock:
1709
1695
1023
1094
3361
2063
12C
hold
GGAACTGACGGTTAGCCTGTCAGCTCTTTGCTCAGACCGGCAAGA
GCCACAGCTTCGCTCGCCACTCATTGTCTGTGGCCCTGACCAGTG
CGCCCTGGTGCTTTTAGTGCCGCCCGGGCCCGGAGGGGCAGCCT
CTTCTCACTGCAGTCAGCGCCGCAACTATAAGAGGCCTATAAGAG
GCGGTGCCTCCCGCAGTGGCTGCTTCAGCCCAGCAGCCAGGACA
GCGAACCATGCTGCCTGCGGCCCGCCTCCAGACTTATTAGAGCCA
GCCTGGGAACTCGCATCACTGCCCTCACCGCTGTGTCCAGTCCCA
CCGTCGCGGACAGCAACCACAGTCGTCAGAACCGCAGCACAGAAC
CAGCAAGGCCAGGCAGGCGATATCCCTATTAATATTCCGGAGTAT
ACGTAGCCGGCTAACGTTAACAACCGGTACCCCATTGTATGGGAT
CTGATCTGGGGCCTCCGTGCACATGCTTTACATGTGTTTAGTCGA
GGTTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTT
CCTTTGAAAAACACGATGATAATATGGCCACAACCATGCCCAAGA
AGAAGAGGAAGGTGTCCAATTTACTGACCGTACACCAAAATTTGC
CTGCATTACCGGTCGATGCAACGAGTGATGAGGTTCGCAAGAACC
TGATGGACATGTTCAGGGATCGCCAGGCGTTTTCTGAGCATACCT
GGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGCGGCATGGTGCA
AGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGATGTTC
GCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAA
CTATCCAGCAACATTTGGGCCAGCTAAACATGCTTCATCGTCGGT
CCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTGGTTA
TGCGGCGGATCCGAAAAGAAAACGTTGATGCCGGTGAACGTGCAA
AACAGGCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTT
CACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGG
CATTTCTGGGGATTGCTTATAACACCCTGTTACGTATAGCCGAAAT
TGCCAGGATCAGGGTTAAAGATATCTCACGTACTGACGGTGGGAG
AATGTTAATCCATATTGGCAGAACGAAAACGCTGGTTAGCACCGC
AGGTGTAGAGAAGGCACTTAGCCTGGGGGTAACTAAACTGGTCGA
GCGATGGATTTCCGTCTCTGGTGTAGCTGATGATCCGAATAACTA
CCTGTTTTGCAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGT
GTTGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTG
GAAGGGATTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAG
GATGACTCTGGTCAGAGATACCTGGCCTGGTCTGGACACAGTGCC
CGTGTCGGAGCCGCGCGAGATATGGCCCGCGCTGGAGTTTCAATA
CCGGAGATCATGCAAGCTGGTGGCTGGACCAATGTAAATATTGTC
ATGAACTATATCGTAACCTGGATAGTGAAACAGGGGCAATGGTGC
GCGTGCTGGAAGATGGCGATTACGCATCGCGTGAATTCTACCAAT
TACTCG
B6 Wntl-Cre 3' homology gblock:
CTCACACCATGGCTCACAAAGCTTCTAGAGCTCGCTGATCAGCCT
CGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCC
CGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTC
CTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCA
TTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGG
ATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCT
ATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCGGTACCTCAACT
ATAGCTAGCATGCGCAAATTTAAAGCGCTGATATCGATCGCGCGC
AGATCTCTTTTCCAGGGCCTGAGCAAGGACCCTGAGATCCTGACC
CTTGGATGACCCTAAATGAGACCAACTAGGGATCCAGGTCTCCTG
AGAGAAAAGCCTGCTCAAAAGCTCCTGCAGGGCTCTTCCTCCTGT
TCTGGCAGCAGCTGGTTAAGTGATGAGGACAAGTGTGTCACCTGA
TGGGGACTCAGCACACCAACAGTCCAGCTCTCCTAGTGCAAGAGC
TGGGGAGGTAGCAGCAATGAAAGGAAAGGATAGCCATGACTACAT
CCTGAGAGGGGGAGGGGAAGCTCAAGCAGAAAGGGTGTCATTGC
CCCTGGGAGGCTATCAACCTTTTCTGCAGTCTGAGCTTTGAGCAG
TGGAAGGCCCACCTCTTACACTCTTCCTGGAAATTCTTTATTAGCA
ACCCAACCCTAACCTACAGGTAAGGGACATCCAGGAACAAGCCAT
GGGTTAGAGCTGGAAAGATGGCTCAGAGGTTAAGAGCACTGGCT
GCTCTTCTAGAAGTCCTGAGTTCAATTCCCAGCAACCACATGGTG
ACTCACAACCATCTGTTAATGGGATCTGGTGCACTCTTCTGGTGT
GTCTGAAGACAGCTATGGTGTGCTCATATAAATAATAATAAAGAA
ATGATATTAAAGAAAAGCCATGGGTTAACAGTGGGCCCTAAACTT
GAACTAGAAAACTTAAAGATGCTCATAGGGAAGAAGAAAAGAGCA
GAAAGC
Below are the Cas9 target sites used for the DM Analgesia integration into
the B6 Wntl-Cre2 mouse (PAM is in parenthesis, not used in guide design):
ggtaatcgccatcttccagc(agg)DALinalgesia-1
DMAnalgesia2
DM.Anaigesia.-3
DMAnalgesia-4
aattactcgacctcacacca(tgg)
ggtagaattcacgcgttaat(ggg)
gcaactagaaggcacagtcg(agg)
Below are scores from various guide analysis software used to analyze for
more effective guides (Oliveros et al. 2016)(Chari et al. 2017).
Gd reaking Cas sgRNA Scorer 2.0
DMAnalgesia_1
DMAnalgesia_2
DMAnalgesia-3
DMAnalgesia4
91
91.4
98.1
86.1
0.131603259
-0.090439974
-0.771734077
1.409282225
Below is the analysis from the Broad Designer tool (Doench et al. 2014).
a9INA CIA Target Cut TargotTawa Target Out On-Targt On-Target Eftaoq Oal'erge OU-Targeo CAMMDNAe
Otade -Ovensam Sm. (iotmd NA~t RUIOt SV Sank Bak ReenkIWAutna- anoe S7d 45 & Aitk.J CL6647 21 40 27
28aa n s 57 446 12.8 Aeimuthl.O 0.3004 4 2 84
4 aanum.. 1"4 188 446 29.9 Axmll.120 0.907 4 1i 4
UC floxed SCN9a
Full sequence can be found at (https://benchling.com/s/seq-
f4OCv9txNVCj4kHU4wPm).
Below is the list of primers used for UC floxed SCN9a, the plasmid that was
designed to add lox around key exons of the SCN9a gene encoding the Nav1.7
sodium ion channel.
DN141 agacttagggacccUttgacttgatcggca
cgtaaga
DN204 aagaggacatccggUATACATTTC
AGTTTGAAAAACAGAAAACT
GCATGTG
DN206 AGAGTTGCACCAUCGATAAC
TTCGTATAATGTATGCTATAC
GAAGTTATTCACTTCTTTGA
GATGGAGACAGTC
DN207 CATGGGGCCAATAGAGGAAA
ATATAACTTCGTATAGCATA
CATTATACGAAGTTATCTTCA
GTGTCAACCCACAAGTG
DN208 GGTTGACACTGAAGATAACT
TCGTATAATGTATGCTATAC
GAAGTTATATTTTCCTCTATT
GGCCCCATGTAAT
DN209 agggtccctaagtcUCTCGAGTTTC
TTCAAGGTCATAACTAATAG
GAGACTAA
DN369 accggatgtcctctUggtagaaaatcaaa
ggatettcttgaga
DN373 ATGGTGCAACTCUAAAAGTG
AcGGCATGCAGGAATATGAA
CAGAGGCACACCAcGCATAT
TCATCTTTAAGTGAAAATGC
65.9 FWD USER primer UC Gaia
for floxed
65.2 FWD USER primer 5'
homology with J4
67.2 FWD USER primer floxed 1
with lox site and recoding
67.7 REV primer for flox 1 with lo
and homology to flox 2
65.4 FWD primer for flox 2 with
XhoI
65.7 REV USER primer for flox 2
with XhoI and J5 for UC BB
attachment
64.8 REV USER primer for UC
BB
70.7 REV USER primer for new
PAM edit SCN9a
TTCATTT
ATGCTATACGAAGTTATTATT
CAGAGATTTCTGCATTAGAA
TTTGTTC
AGTTATGACCTTGAAGAAAC
TCGAGATAACTTCGTATAAT
GTATGCTATACGAAGTTATT
ATTCAGAGATTTCTG
60.7 FWD
2kb
65.4
primer 1 for SCN9a
FWD primer 2 SCN9a 2kb
DN374
DN375
DN376
Below are DN377
the PCR
CTCGAGATTGAGGATTCTTA 59.6 REV primer 1 SCN9a 2kb
TCACAACTTATTTGCA
agggtccctaagtetCTCGAGATTG 64.5 REV primer 2 SCN9a 2kb
AGGATTCTTATCACAAC
settings for
the DNA fragments amplified for UC floxed SCN9a assembly.
1 UC
Backbone
2 Floxed
exon 14
3 Floxed
exon 15
4 Flox
exon
14+15
5 SCN9a 5'
homology
6 SCN9a 3'
homology
7 SCN9a 3'
homology
for gibson
DN141 DN369 UC Rope 55 65 1 min 1872
DN206 DN207 mouse 56 67 45 see 1239
gDNA
DN208 DN209 mouse
gDNA
DN206 DN209 PCR
2+PCR 3
DN204
DN374
DN375
DN373 mouse
gDNA
DN376 mouse
gDNA
DN377 PCR 6
55 65 45 sec
63 66 1 min 30
see
55 67.5 45 sec
54 60 1 min 30
see
60 65 1 min 30
sec
1266
2435
1038
2017
2082
i--I
All of these PCRs were two temperature PCRs, where the first five cycles are
at the first temperature and the last twenty-five cycles at the second
temperature. Below is the thermocycler program:
Stage I Stage 2 tage 3 Stage 4
98C
30 sec
98C T1
10 sec 15 sec
72C
Ext
98C
10 sec
T2
15 sec
72C
Ext
72C
7 min
12 C
hold
Below are the Cas9 target sites used for the UC floxed SCN9a integration
into the standard C57BL6/J mice (Taconic B6) (PAM is in parenthesis, not
used in guide design
SUN9a-1
SCN9&j2
SCN9a-.3
SCN9a-4
ATGGTGCAACTCTAAAAGTG(AGG)
TCACTTTTAGAGTTGCACCA(TGG)
AATATGAACAGAGGCACACC(AGG)
CCATCTCAAAGAAGTGACCA(TGG)
Below are scores from various guide analysis software used to analyze for
more effective guides (Oliveros et al. 2016)(Chari et al. 2017).
E2~~~~~~~~~~E Ibra hi-.'*U'1..~-* 'rjl'V -aa 11.
SCN9a1..
SCN9aj"
SCN9a_3
SCN9a_4
84.3
81.8
73.2
61
0.291880669658
0.00213112153575
0.0995941647656
0.622321078208
Below is the analysis from the Broad Designer tool (Doench et al. 2014).
agtNA Cut Target Cut Target Total Target On-Target On-Target On-Target Off-Target Combined
Guide Orientation Poaition (1-baaed) Length Langth cut % Ruleset Efficacy Score Rank Rank Rank
SCN9aJI antineae 268 267 518 52 Azimuth.2O0 0.689 5 8 2
SCNBa2 aenae 281 280 518 54.6 Azimuth-.0 0.68 2 12 4
SCN9a_3 antiaenae 238 235 513 45.8 AzimuthL..20 0.5665 11 2 3
SCN9X_ antiaanae 287 286 518 55.8 Azimuth.2.0 0.6254 6 13 6
UC floxed SCN7a
Full sequence can be found at(https://benchling.com/s/seq-
zGglVvCaHbADu3ZbKiAM).
Below is the list of primers used for UC floxed SCN7a, the plasmid that was
designed to add lox around a key exon of the SCN7a gene encoding the Nax
sodium-like ion channel.
*Primer Sequenc  Tm Inf
DN141 agacttagggacccUttgacttgatcgg 65.9
cacgtaaga
DN214 AGCATACATTATACGAAGU
TATTGGAGCCAGGTTTCCT
TAAAGT
DN215 ACTTCGTATAATGTATGCU
ATACGAAGTTATCGAGGAA
GCAAGATTTTGGCAT
DN216 acgccatgggcaUTCTCCAGAAT
ATCACTTTACTCTAGGC
DN260 aACCGGTgctttUgacttgatcggc
ac
DN350 atgcccatggcgUATAACTTCGT
ATAATGTATGCTATACGAA
GTTATTATAAGATGGTATA
ATTGTGGTGATGAAAATCA
TTTTT
DN351 agggtccctaagtcUAAATTTCAT
TGTAACTGCTTAATCCAAT
CCAGATAGTT
DN352 CTTCCATATACCTGTATGG
AATTGGAAACTATAGGTggt
DN368
agaaaatcaaaggatcttettgaga
TGGAGCCAGGTTTCCTTAA
AGTGAGAGAACAAACACTA
ACTTAGAAACAGGTAGTAT
TACAAGCcGCAGACAAGCA
iTTTTACTAACAAATGCCTAT
GGCAAGCgCATTTTCAGTT
GAGCCCCGTC
DN370 caagcagcagattacgcgcagaaaaaa
aggatctcaagaagatcctttgattttct
accaagaggacatccggtACCTATA
GTTTCCAATTCCATACAGG
IT
DN371 TGTATGCTATACGAAGTTA
TTATAAGATGGTATAATTG
TGGTGATGAAAATCATTTT
'TAAAGC
63.2
64.8
65.8
FWD USER primer UC Gaia
for floxed
Rev USER primer 5' homology
with part of lox site to disrupt
cut sites
Fwd USER primer floxed exon
with part of lox site
Rev USER primer floxed exon
with J2
63.4 Fwd USER primer for UC BB
67.2 FWD USER J2 primer for
SCN7a 3' homology 2kb
64.7
65.5
71.61
70.5
63
REV USER J5 primer for
SCN7a 3' homology 2kb
REV OEPCR for UC BB for
SCN7a
REV ultramer with the extra
PAM changes for 4 guides
SCN7a
FWD primer for 5' SCN7a (to
go with DN368)
FWD primer 1 for 3' homology
2kb (half the lox site)
i
Below are the PCR settings for the DNA fragments amplified for UC floxed
SCN9a assembly.
SCN7a
floxed
DN215 DN216
exon
3' DN371 DN351
homology
2kb pt.I
hon
2kt
3' DN350 DN3511
ology
pt.JI
mouse 1 55 64 Mi sec
gDNA
mouse 58 63 1 min
gDNA
PCR 2
4 OEPCR DN260 DN352 UC Gaia
for UC
BB and 5'
hom for
SCN7a
62
55
5 floxed DN370 DN368 mouse 55.5
SCN7a 5' gDNA
homology
with
PAMs
6 UC BB
+SCN7a
5' hom
DN141 DN214 PCR
4+PCR 5
66
63
71
1 min
1 min
1 min
70 65 , 2 mins
All of these PCRs were two temperature PCRs, where the first five cycles are
at the first temperature and the last twenty-five cycles at the second
temperature. Below is the thermocycler program:
Stage 1 Stage 2 Stage 3 Stage 4
98 C 98 C
30 sec 10 sec 1
T1 72 C 98 C T2 72 C
5 sec Ext 10 see 15 sec Ext
1
2
3
2000
2000
1850
1000
2800
72 C
7 min
12 C
hold
I
~1i
Appendix II
IACUC Survey
Below is the exact language and logic if the survey distributed to the IACUC
members through the AALAS list-serv. The survey was designed and
distributed using Qualtrics.
IACUC Survey
Q1 Thank you for taking the time to complete this 5 minute survey!
Participation is voluntary and you may decline to answer any questions or
stop at any point. This survey is confidential and your personal information
will not be stored.
I am a researcher working in the Esvelt Lab at MIT on a project aiming to
reduce animal suffering and improve scientific outcomes by engineering
several strains of "inducible pain-free" mice. When fed a small molecule
inducer, these mice will permanently lose the ability to feel a certain type of
pain. In particular, mechanosensory, inflammatory, and classes of
neuropathic pain are being targeted. Investigators would induce the
appropriate engineered mouse strain before performing a procedure, thus
abating perception of that form of pain from the animal during the duration
of the experiment and hopefully causing less suffering than would occur with
the standard analgesics.
While developing these strains of mice, I am interested in determining what
type of information or experimental demonstrations are needed for IACUC
committees to be comfortable with recommending their researchers consider
these mice as a further method of refinement in experimentation. People
outside the scientific community may argue that this project will lead to
additional experiments that might not otherwise receive approval. This
survey aims to ensure that no such outcomes occur through gaining
understanding of IACUC members' opinions and recommendations for the
project. It should be noted that mice are being developed on a nonprofit basis
to enable swift and widespread adoption if appropriate; we are doing this to
reduce animal suffering and benefit science.
This survey has received an IRB exemption because it is anonymous and
poses minimal risk. The survey results will be written up as part of my
Master's Thesis along with the design and preliminary results for the
inducible pain-free mice. With sufficient data from this survey, I plan to
publish the results in a peer-reviewed article in a scientific journal or
otherwise make the results available to the IACUC community.
Feel free to contact devora@mit.edu with any question or comments.
Q2 I understand the procedures described above and I agree to participate in
this study.
Q I consent (1)
( I do not consent (2)
End of Block: Consent
Start of B)Iock IACUC info
-1
Q3 Which member of the IACUC committee do you represent?
Veterinarian (1)
O Non-scientist (2)
( Non-affiliated member (representing community) (3)
OPracticing scientist experienced in animal research (4)
O Chairperson (5)
Administrator (6)
()Other (7)
Q4 How many members are there on your IACUC committee?
Q5 How does your IACUC typically review protocols?
) Designated Member Review (mainly or only) (4)
( Full Committee Review (mainly or only) (5)
C) Both depending on circumstances (6)
Start of Block: Category
Q6 What percentage of protocols submitted monthly for review to your
IACUC involve Category D animals? (Category D is classified as animals
subjected to potentially painful or stressful procedures for which they receive
appropriate anesthetics, analgesics and/or tranquilizer drugs.)
C 0-20% (1)
()21-40% (2)
) 41-60% (3)
0 61-80% (4)
O >80% (5)
0 Other (6)
Q7 What percentage of protocols submitted monthly for review to your
IACUC involve Category E animals? (Category E is classified as animal use
activities that involve accompanying pain or distress to the animals and for
which appropriate anesthetic, analgesic, tranquilizing drugs or other
methods for relieving pain or distress are not used or delayed for scientific
purposes. Scientific justification has to be provided.)
S0-20% (1)
(21-40% (2)
( 41-60% (3).
) 61-80% (4)
0 >80% (5)
O Other (6)
Q8 In your opinion, is there is a need for further refinement strategies for
research involving Category D and Category E animals?
Q)Yes (1)
0 No (2)
( D Other (3)
Snd of Block Cegfrm i
Start of Block: Refinement
Q9 In your opinion, how would you rate the problem of animal pain in the
Category D studies performed at your institution?
0 Low (Either procedures are not painful or the pain is well controlled.)
(1)
(. Moderate (Painful procedures are limited, and pain is controlled the
best we can, but animals do sometimes experience some pain.) (2)
( ) High (Procedures are very painful and controlling pain is a challenge.)
(3)
Q10 If specific pain pathways in an animal model could be lastingly shut
down prior to experimentation, could this be considered to be a "refinement"
strategy for experimentation?
( Yes (1)
) No (2)
Q11 If mechanosensory and inflammatory pain perception could be lastingly
shut down prior to experimentation, should such an animal be classified in a
similar way to an animal that receives anesthesia or an analgesic?
0 Yes (1)
(9 No (2)
Q12 Would you be willing to approve the use of additional animals in
Category D experiments in order to determine the extent to which the new
method reduces suffering without interfering with experimental outcomes?
O Yes (1)
C)) No (2)
Q13 Would you be willing to approve the use of additional animals in
Category E experiments in order to determine the extent to which the new
method reduces suffering without interfering with experimental outcomes?
0 Yes (1)
o No (2)
Q14 How many peer-reviewed studies in a relevant area of research would
you find necessary to be comfortable with an investigator using this mouse
model in their research in place of traditional analgesics or anesthesia?
O 1 (1)
0 2 (2)
03 (3)
04 (4)
0 5+ (5)
Q15 Assuming sufficient peer-reviewed studies show that this mouse model
reduces suffering without interfering with the pathways being studied by
researchers, would you be willing to require its use by investigators?
) Yes (1)
0 Yes, if the investigators cannot use traditional analgesics or anesthesia
(2)
No, but I could recommend it as a further refinement strategy (3)
O No (4)
Start of Block: Further Comments
Q16 If you have any final comments or recommendations regarding the
survey, please feel free to write below.
IACUC Survey Results
Default Report
IA CUC Survey
August 20th 2018, 10:33 am MDT
Q2 - I understand the procedures described above and I agree to participate
in this study.
# Field Minimum
1 Unknown
Maximum
1.00
Mean
1.00 1.00
Std
Deviation
0.00
Variance Count
0.00 23
Question
I consent
Unknown
100.00%
I do not consent 0.00%
Total
23
0
Q3 - Which member of the IACUC committee do you represent?
# Field Minimum Maximum StdDeviation Variance Count
1 Unknown 1.00 7.00 4.52
Question Unknown
Veterinarian
1
2
23
0
2.18 4.77 23
1 21.74% 5
2 Non-scientist 4.35% 1
3 Non-affiliated member (representing community) 0.00% 0
4 Practicing scientist experienced in animal research 13.04% 3
5 Chairperson 13.04% 3
6 Administrator 30.43% 7
7 Other 17.39% 4
Total Total 23
Question Unknown Total
and chair 100.00% 1 1
Compliance 100.00% 1 1
Coordinator 10000% 1 1
Statistician 100.00% 1 1
Q4 - How many members are there on your IACUC committee?
~30
8
8
8
7
7
6
6
6
23
19
17
17
16
16
15
15
15
15
14
14
11
10
~30
23
14
8
11
14
15
8
6
8
19
6
17
15
15
16
6
7
15
17
7
10
16
Q5 - How does your IACUC typically review protocols?
# Field Minimum Maximum Mean Std
Deviation Variance Count
1 Unknown 4.00 6.00 5.26
Question Unknown
4 Designated Member Review (mainly or only)
5 Full Committee Review (mainly or only)
Both depending on circumstances
100.00% 4 4
100.00% 9 9
100.00% 10 10
0.74 0.54 23
Total
6
Q6 - What percentage of protocols submitted monthly for review to your
IACUC involve Category D animals? (Category D is classified as animals
subjected to potentially painful or stressful procedures for which they receive
appropriate anesthetics, analgesics and/or tranquilizer drugs.)
# Field Minimum Maximum Mean Std
Deviation
Variance Count
1 Unknown 1.00 6.00 3.41
Question
0-20%
21-40%
1
2
3
4
5
6
41-60%
61-80%
>80%
Other
Unknown
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
Question
I don't know for sure, but think it would be >80%.
varies, and I can't quickly access numbers now
i dont know
in many of our studies anesthesia is used for
restraint not specifically for pain management
Unknown Total
0.00% 0 0
0.00% 0 0
100.00% 1 1
100.00% 1 1
Q7 - What percentage of protocols submitted monthly for review to your
IACUC involve Category E animals? (Category E is classified as animal use
1.40 1.97 22
Total
2
4
6
5
3
2
2
4
6
5
3
2
activities that involve accompanying pain or distress to the animals and for
which appropriate anesthetic, analgesic, tranquilizing drugs or other
methods for relieving pain or distress are not used or delayed for scientific
purposes. Scientific justification has to be provided.)
# Field Minimum Maximum Std
Deviation Variance Count
I Unknown
I
2
3
A
5
6
1.00 6.00 1.77
Question
0-20%
21-40%
41-60%
r- I 0U /0
>80%
Other
Question
varies, and I can't quickly access numbers now
i dont know
0
0.00% 0 0
100.00% 1
100.00% 1
Q8 - In your opinion, is there is a need for further refinement strategies for
research involving Category D and Category E animals?
1.51 2.27 22
Total
15 15
Unknown
100.00%
100.00%
0.00%
1. flfA (~rA/
lu U . W U/0
0.00%
100.00%
4
0
4
0
1 1
0
2
0
2
Unknown Total
1
1
# Field Minimum Maximum stdMean D t
Deviation Variance Count
1 Unknown 1.00 3.00 1.36
Question
1 Yes
No2
3 Other
Unknown
100.00%
100.00%
100.00%
Question
I'm not sure it is a 'need' but it would be highly
desirable
Category D I think is managed well. Category E
could be further evaluated
This is a regulatory requirement
0.00% 0 0
100.00% 1 1
100.00% 1 1
Q9 - In your opinion, how would you rate the problem of animal pain in the
Category D studies performed at your institution?
# Field Minimum
1 Unknown
Maximum
1.00
Mean
3.00 1.59
Std
Deviation
0.58
Variance Count
0.33 22
Question Unknown
Low ( Either procedures are not painful or the
Total
100.00% 10 10pain is well controlled.)
0.64 0.41. 22
Total
16 16
4
2
4
2
Unknown Total
1
Moderate (Painful procedures are limited, and
2 pain is controlled the best we can, but animals do
sometimes experience some pain.)
3 High (Procedures are very painful and
controlling pain is a challenge.)
100.00% 11 11
100.00% 1 1
Q10 - If specific pain pathways in an animal model could be lastingly shut
down prior to experimentation, could this be considered to be a "refinement"
strategy for experimentation?
# Field Minimum Maximum StdMean D t
Deviation Variance Count
I Unknown 1.00 2.00 1.14
Question
1
2
Yes
No
Unknown
100.00%
100.00%
Q11 - If mechanosensory and inflammatory pain perception could be lastingly
shut down prior to experimentation, should such an animal be classified in a
similar way to an animal that receives anesthesia or an analgesic?
# Field Minimum Maximum Mean Std Variance
Deviation Count
1.00 2.00 1.35
0.34 0.12 22
Total
19 19
3 3
I Unknown 0.48 0.23 20
Question Unknown
1 Yes
2 No
100.00%
100.00%
13
7
13
7
Q12 - Would you be willing to approve the use of additional animals in
Category D experiments in order to determine the extent to which the new
method reduces suffering without interfering with experimental outcomes?
# Field Minimum Maximum StdMean D to
Deviation Variance Count
1 Unknown 1.00 1.00 1.00
Ques'tion
1
2
Yes
No
0.00
Unknown
100.00%
0.00%
0.00 22
Totl
22 22
0 0
Q13 - Would you be willing to approve the use of additional animals in
Category E experiments in order to determine the extent to which the new
method reduces suffering without interfering with experimental outcomes?
# Field Minimum Maximum Mean Std Variance
Deviation
1.00 2.00 1.19
Count
# Total
1 Unknown 0.39 0.15 21
Question
1 Yes
2 No
Unknown
100.00%
100.00%
Total
17
4
17
4
Q14 - How many peer-reviewed studies in a relevant area of research would
you find necessary to be comfortable with an investigator using this mouse
model in their research in place of traditional analgesics or anesthesia?
# Field Minimum Maximum Std
Deviation
Variance Count
1 Unknown 2.00
Qoeiin
11
2
3
4
5
2
3
4
5+
5.00 4.00
Tn known
0.00%
100.00%
100.00%
100.00%
100.00%
Q15 -Assuming sufficient peer-reviewed studies show that this mouse model
reduces suffering without interfering with the pathways being studied by
researchers, would you be willing to require its use by investigators?
Std# Field Minimum Maximum Mean D t
Deviation Variance 
Count
1.00 3.00 2.45
1.02 1.05 21
TotaqI1
0 0
1, 1
8
2
8
2
10 10
I Unknown 0.78 0.61 22
Question Unknown Total
1 Yes 100.00% 4 4
2 Yes, if the investigators cannot use traditional 100.00% 4 4
analgesics or anesthesia
No, but I could recommend it as a further3100.00% 14 14
refinement strategy
4 No 0.00% 0 0
Q16 - If you have any final comments or recommendations regarding the
survey, please feel free to write below.
1 am concerned tis- - ur vey is tU- br-ad a --d doe nut ares the numeroUs
strain specific, sex specific responses to pain and recognition of pain. This
technology would in my mind require validation of proper pain control
similar to that used to validate proper management and control when
paralytic agents are employed until such measurements and validations
are confirmed
For this question: "If mechanosensory and inflammatory pain perception
could be lastingly shut down prior to experimentation, should such an
animal be classified in a similar way to an animal that receives anesthesia
or an analgesic?" my answer would have changed to "yes" if only analgesics
were referenced. I would not feel comfortable foregoing anesthetics for
surgery as there are other components to consider (such as animals
remaining motionless)
If mechanosensory and inflammatory pain perception could be lastingly
shut down prior to experimentation, should such an animal be classified in
a similar way to an animal that receives anesthesia or an analgesic? This
question was hard for me to definitively answer. I answered "No", but
there may be cases where I would not agree - for instance if the animal was
treated to develop a physiological response (illness) that would cause the
animal to loose some ability, I may want it to be still classified as cat. "D"
)possibly "E"???) Also, I am NOT in favor of the IACUC mandating which
animal a PI uses, it is the PI's job to justify the use of the animal it chooses.
The IACUC can ask questions about the justification, but to blanket
require an animal model like this I would be very hesitant to support
I found this project worth a Nobel Price! Wonderful! The main concern in
IACUC committees is basically making sure that whoever is working with
the animals are doing their best to guarantee their well being. Having an
animal that cannot experience pain is the best that you could ask for,
IACUC wise. However, even though I did say I would approve more
animals for a study with this characteristics, is still challenging to
maintain a balance when as IACUC, you also want to have fewer animals
being used. Wonderful project! Please keep the IACUC ListServe updated
of your outcomes, posters or any other progress made towards this goal, I
can't wait to hear that this mouse strain is available to be able to
recommend it to every other friend I have in the scientific community. Best
luck!
Hi, your survey does not allow for additional qualification of the yes or no
answers. Those comments might be useful to your discussion section.
There are several things that are taken into account when reviewing an
animal use proposal, pain management through pharmacological means
(general anesthesia, NSAIDs, opioids, local anesthesia, etc) as well as non-
pharmacological techniques (Heat/cold application, physical therapy,
socialization, human contact, enrichment, etc) are one aspect of the review.
The other component to take into consideration is distress to the animal
and research staff. Developing a model without pain receiving pathways is
a refinement that potentially addresses pain, but I would require scientific
justification for withholding analgesia and a thorough description on how
distress would be appropriately managed (example: could the animal be
conditioned or acclimated to the procedure(s)?). There would need to be
strong scientific justification and a complete literary search. It is difficult to
make a determination without having a full understanding of the entire
proposal.
This is a worthy goal, but the basic premise of pain categorization in US-
based research is that if we would feel pain, we should infer that the
animal will feel pain. Modifiable pathways that demonstrably minimize or
eliminate pain would be a great refinement to add to our options, but that's
not going to change the categorization criteria, particularly since most of us
use procedure-based categorization for the most part, rather than
individual animal-based assessments.
I answered the D and E questions for the highest category. I just went back
through two months of protocols and counted -- I don't have a long term
percentage on that. I suspect that answers to these specific knowledge
questions will be unreliable. // I have no idea how many studies I would
need to be comfortable -- one or two thorough and good ones might be
enough! // The biggest issue I see with this interesting idea is that many
researchers are using genetically-modified strains already and may be
averse to adding modifications. They even resist using male mice if
previous studies have used females -- changes like that can affect the
outcome. // Some researchers do studies in which the development of an
inflammatory condition is the outcome. They resist analgesics, because they
could undermine the inflammation. But perhaps a pain-free mouse model
would be OK there, if the lack of pain did not affect the inflammatory
process.
pain perception would only be one criteria, IACUC must still weigh tissue
damage, impact on normal behaviors, etc. when determining if a particular
model is appropriate.
the pain system especially peripheral nerves interacts with all body
systems and tissues. if the pain system is shut down via genetic approaches
from birth then I would expect their body systems to not be normal and as
such data from these animals may not approximate to normal animals. this
situation would not be comparable to short term use of a analgesic or
anesthetic in a mature animal which i would suggest is much less likely to
impact experimental results.
Good luck with your survey - pain free mouse strains sounds very
intriguing!
This would be great!
